

# Biliary Tract Cancers

New England Journal of Medicine

341, 1368-1378

DOI: 10.1056/nejm199910283411807

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography.. American Journal of Roentgenology, 1998, 170, 1491-1495.	2.2	98
2	Pathology of the liver. Current Opinion in Gastroenterology, 2000, 16, 200-207.	2.3	0
3	Biliary tract cancer. Current Opinion in Gastroenterology, 2000, 16, 437-443.	2.3	8
4	Diagnostic imaging approaches and relationship to hepatobiliary cancer staging and therapy. Journal of Surgical Oncology, 2000, 19, 94-115.	1.4	30
5	Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen?. Hepatology, 2000, 31, 247-248.	7.3	28
6	Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. Hepatology, 2000, 31, 291-298.	7.3	183
7	Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transplantation, 2000, 6, 786-794.	2.4	111
8	Treatment options for other hepatic malignancies. Liver Transplantation, 2000, 6, s23-s29.	2.4	52
9	Early detection and treatment of cholangiocarcinoma. Liver Transplantation, 2000, 6, s30-s34.	2.4	104
10	Parvovirus B19-Related Anemia in an HIV-Infected Patient: Rapid Control after Production of Neutralizing Antibodies during Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 2000, 132, 1011.	3.9	13
11	Hemolytic Uremic Syndrome in a Patient Treated with Clopidogrel. Annals of Internal Medicine, 2000, 132, 1006.	3.9	12
12	Management of Fibromyalgia. Annals of Internal Medicine, 2000, 132, 1005.	3.9	2
13	Isotretinoin in Respiratory Papillomatosis. Annals of Internal Medicine, 2000, 132, 1007.	3.9	9
14	Epidemiologic Relation between HIV and Invasive Pneumococcal Disease in San Francisco County, California. Annals of Internal Medicine, 2000, 132, 1009.	3.9	1
15	The Relation between Somatic Symptoms and Depression. New England Journal of Medicine, 2000, 342, 658-659.	27.0	2
16	Idiopathic Eosinophilia. New England Journal of Medicine, 2000, 342, 659-661.	27.0	1
17	Multidrug-Resistant Salmonella enterica Serotype Typhimurium DT104. New England Journal of Medicine, 2000, 342, 661-661.	27.0	4
18	Respiratory Distress Associated with Zanamivir. New England Journal of Medicine, 2000, 342, 661-662.	27.0	63

#	ARTICLE	IF	CITATIONS
19	Recovery of Heart Rate after Exercise. New England Journal of Medicine, 2000, 342, 662-663.	27.0	14
20	Biliary Tract Cancers. New England Journal of Medicine, 2000, 342, 663-664.	27.0	11
21	Toll Genes and Responsiveness to Bacterial Endotoxins. New England Journal of Medicine, 2000, 342, 664-665.	27.0	9
22	Treatment of Neurogenic Incontinence with Botulinum Toxin A. New England Journal of Medicine, 2000, 342, 665-665.	27.0	212
23	Long-term outcome in patients with advanced hilar bile duct tumors undergoing palliative endoscopic or percutaneous drainage. Zeitschrift Fur Gastroenterologie, 2000, 38, 483-489.	0.5	52
24	Hepatic resection: Effective treatment for primary and secondary tumors. Surgery, 2000, 128, 686-693.	1.9	47
25	BIOLOGIC AND CLINICAL SIGNIFICANCE OF LYMPHADENECTOMY. Surgical Clinics of North America, 2000, 80, 1631-1673.	1.5	64
26	Changing Strategies in Diagnosis and Management of Hilar Cholangiocarcinoma. Liver Transplantation, 2000, 6, 786-794.	2.4	39
27	Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointestinal Endoscopy, 2001, 53, 500-504.	1.0	113
30	A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Annals of Oncology, 2001, 12, 501-504.	1.2	39
31	Biliary tract cancer. Current Opinion in Gastroenterology, 2001, 17, 450-457.	2.3	11
32	Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Annals of Oncology, 2001, 12, 183-186.	1.2	160
33	Photodynamic therapy in the biliary tract. Current Gastroenterology Reports, 2001, 3, 154-159.	2.5	8
34	Biliary cancer growth factor pathways, cyclooxygenase and potential therapeutic strategies. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 363-372.	2.8	61
35	Differing rates of loss of DPC4 expression and p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer, 2001, 91, 1332-1341.	4.1	114
36	Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Digestive Diseases and Sciences, 2001, 46, 1387-1392.	2.3	35
37	Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes and Control, 2001, 12, 959-964.	1.8	220
38	Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology, 2001, 33, 43-51.	7.3	60

#	ARTICLE	IF	CITATIONS
39	A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33, 464-470.	7.3	4,112
40	Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology, 2001, 33, 1029-1035.	7.3	239
41	Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology, 2001, 33, 1353-1357.	7.3	915
42	Autosomal recessive polycystic kidney disease in adulthood. Nephrology Dialysis Transplantation, 2001, 16, 1648-1652.	0.7	89
43	Gallbladder carcinoma secondary to repetitive hepatic arterial chemoembolization. American Journal of Gastroenterology, 2002, 97, 1079-1080.	0.4	2
44	Interferon for Postresection Recurrence of Hepatocellular Carcinoma. American Journal of Gastroenterology, 2002, 97, 3200-3202.	0.4	1
46	Cyclooxygenase-2 and ERBB-2 in Cholangiocarcinoma: Potential Therapeutic Targets. Seminars in Liver Disease, 2002, 22, 303-314.	3.6	78
47	Diagnosis of Biliary Strictures in Conjunction with Endoscopic Retrograde Cholangiopancreatography, with Special Reference to Patients with Primary Sclerosing Cholangitis. Endoscopy, 2002, 34, 909-916.	1.8	124
48	Past, Present, and Future of Endoscopic Retrograde Cholangiopancreatography: Perspectives on the National Institutes of Health Consensus Conference. Mayo Clinic Proceedings, 2002, 77, 407-412.	3.0	24
49	Cholangiocarcinoma: The "Other" Liver Cancer on the Rise. American Journal of Gastroenterology, 2002, 97, 3199-3200.	0.4	22
50	Cholangiocarcinoma: the "other" liver cancer on the rise. American Journal of Gastroenterology, 2002, 97, 3199-3200.	0.4	19
51	Interferon for postresection recurrence of hepatocellular carcinoma. American Journal of Gastroenterology, 2002, 97, 3200-3202.	0.4	1
52	p16INK4a Promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology, 2002, 123, 1090-1098.	1.3	92
53	Optical coherence tomography of the biliary tree during ERCP. Gastrointestinal Endoscopy, 2002, 55, 84-88.	1.0	90
54	Clinical Imaging with Optical Coherence Tomography. Academic Radiology, 2002, 9, 942-953.	2.5	64
55	Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 2002, 51, vi1-vi9.	12.1	441
56	Bile duct tumours. Current Diagnostic Pathology, 2002, 8, 160-171.	0.4	3
57	Past, Present, and Future of Endoscopic Retrograde Cholangiopancreatography: Perspectives on the National Institutes of Health Consensus Conference. Mayo Clinic Proceedings, 2002, 77, 407-412.	3.0	19

#	ARTICLE	IF	CITATIONS
58	Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 969-983.	1.5	27
59	Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 909-921.	1.5	65
60	Hepatic resection in the treatment of perihilar cholangiocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2002, 11, 893-908.	1.5	22
61	Identifying Contraindication to Resection in Patients with Pancreatic Carcinoma: The Role of Endoscopic Ultrasound. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2002, 16, 109-114.	1.7	17
62	Worldwide trends in mortality from biliary tract malignancies. <i>BMC Cancer</i> , 2002, 2, 10.	2.6	413
63	Review of gemcitabine in biliary tract carcinoma. <i>Seminars in Oncology</i> , 2002, 29, 40-45.	2.2	27
64	Chemotherapy in biliary tract carcinomas: Results in India. <i>Seminars in Oncology</i> , 2002, 29, 46-50.	2.2	2
65	Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. <i>International Journal of Cancer</i> , 2002, 97, 481-488.	5.1	41
66	<i>Helicobacter pylori</i> and the risk of benign and malignant biliary tract disease. <i>Cancer</i> , 2002, 95, 1946-1953.	4.1	90
68	Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation. <i>Journal of Gastroenterology</i> , 2002, 37, 831-839.	5.1	25
69	Clinical role of 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1047-1054.	6.4	109
70	CPT-11 for Bile-Duct and Gallbladder Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Study. <i>International Journal of Gastrointestinal Cancer</i> , 2003, 32, 107-114.	0.4	28
71	Inhibition of cholangiocarcinoma growth by Tannic acid. <i>Hepatology</i> , 2003, 37, 1097-1104.	7.3	54
72	Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. <i>Hepatology</i> , 2003, 38, 158-166.	7.3	34
73	Diagnosis, staging, and treatment of cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 105-112.	0.8	20
74	Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 850-856.	1.7	32
75	Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma. <i>Cancer</i> , 2003, 97, 2783-2790.	4.1	156
76	Infrequent microsatellite instability in liver fluke infection-associated intrahepatic cholangiocarcinomas from Thailand. <i>International Journal of Cancer</i> , 2003, 107, 375-380.	5.1	16

#	ARTICLE	IF	CITATIONS
77	Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2003, 71, 1-10.	3.8	44
78	Intraoperative radiation therapy in the multimodality approach to hepatobiliary tract cancer. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 979-992.	1.5	1
79	Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. <i>Digestive and Liver Disease</i> , 2003, 35, 332-338.	0.9	60
80	Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 41-49.	1.0	198
81	Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 213-219.	1.0	45
82	EUS-guided FNA for the diagnosis of gallbladder masses. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 251-254.	1.0	84
83	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. <i>American Journal of Pathology</i> , 2003, 163, 217-229.	3.8	117
84	Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) $\beta$ -hydroxylase suppress migration of cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2003, 38, 615-622.	3.7	76
85	Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 860-867.	1.0	146
86	Incidental finding of gallbladder carcinoma detected during or after laparoscopic cholecystectomy. <i>European Journal of Surgical Oncology</i> , 2003, 29, 358-360.	1.0	40
87	Primary sclerosing cholangitis. <i>Autoimmunity Reviews</i> , 2003, 2, 305-312.	5.8	44
88	DNA adducts, detected by $^{32}\text{P}$ postlabelling, in human cholangiocarcinoma. <i>Gut</i> , 2003, 52, 586-591.	12.1	21
89	Hepatic and extrahepatic malignancies and primary sclerosing cholangitis. <i>Gut</i> , 2003, 52, 165-165.	12.1	9
90	Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase- $\gamma$ -Specific Inhibitor O1-Hexadecyl- $\beta$ -glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 861-869.	2.5	59
91	Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. <i>Carcinogenesis</i> , 2003, 25, 631-636.	2.8	127
92	The recent decline in gallbladder cancer mortality in Europe. <i>European Journal of Cancer Prevention</i> , 2003, 12, 265-267.	1.3	42
93	Imatinib mesylate (STI571; Glivec)???a new approach in the treatment of biliary tract cancer?. <i>Anti-Cancer Drugs</i> , 2003, 14, 751-760.	1.4	7
94	Pancreatic and hepatobiliary cancer. , 2003, , 178-189.		0

#	ARTICLE	IF	CITATIONS
95	A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periapillary Carcinomas. <i>Chemotherapy</i> , 2003, 49, 154-158.	1.6	61
96	Colon Cancer and Other Gastrointestinal Malignancies. , 2003, , 417-440.		1
98	The Molecular Pathogenesis of Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 127-137.	3.6	95
99	Photodynamic Therapy for Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 177-187.	3.6	55
101	Serum and Bile Markers for Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 139-154.	3.6	163
102	Endoscopic Management of Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 165-175.	3.6	62
103	The Epidemiology of Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 115-125.	3.6	1,054
104	Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. <i>Annals of Oncology</i> , 2004, 15, 478-483.	1.2	129
105	Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. <i>British Journal of Cancer</i> , 2004, 90, 1715-1719.	6.4	39
106	A Proteomic Analysis of Human Bile. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 715-728.	3.8	142
107	Expression of cyclooxygenase-2 in cholangiocarcinoma: Correlation with clinicopathological features and prognosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 582-588.	2.8	16
108	A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. <i>British Journal of Cancer</i> , 2004, 90, 1516-1520.	6.4	126
109	The V599E BRAF mutation is uncommon in biliary tract cancers. <i>Modern Pathology</i> , 2004, 17, 1386-1391.	5.5	40
110	Resectable Hilar Cholangiocarcinoma: Surgical Treatment and Long-Term Outcome. <i>Surgery Today</i> , 2004, 34, 885-890.	1.5	34
111	Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer. <i>Investigational New Drugs</i> , 2004, 22, 193-198.	2.6	89
112	Chemoradiation May Prolong Survival of Patients with Non-Bulky Unresectable Extrahepatic Biliary Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 751-757.	2.0	38
113	The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells. <i>Journal of Molecular Medicine</i> , 2004, 82, 56-63.	3.9	9
114	Preoperative assessment of extrahepatic cholangiocarcinoma with imaging. <i>Abdominal Imaging</i> , 2004, 29, 572-80.	2.0	9

#	ARTICLE	IF	CITATIONS
115	Immunohistochemical Study of DPC4 and p53 Proteins in Gallbladder and Bile Duct Cancers. World Journal of Surgery, 2004, 28, 995-1000.	1.6	48
116	Diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports, 2004, 6, 52-59.	2.5	15
117	Bile duct cysts in adults. British Journal of Surgery, 2004, 91, 1538-1548.	0.3	167
118	Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. Hepatology, 2004, 39, 732-738.	7.3	83
119	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615.	4.1	95
121	Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clinical Gastroenterology and Hepatology, 2004, 2, 209-213.	4.4	283
122	PET imaging in assessing gastrointestinal tumors. Radiologic Clinics of North America, 2004, 42, 1123-1139.	1.8	27
123	Photodynamic therapy in cholangiocarcinoma: an overview. Photodiagnosis and Photodynamic Therapy, 2004, 1, 85-92.	2.6	7
124	The cholangiopathies: Disorders of biliary epithelia. Gastroenterology, 2004, 127, 1565-1577.	1.3	326
125	Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology, 2004, 127, 1787-1797.	1.3	30
126	Magnetic resonance imaging of cholangiocarcinoma. Cancer Imaging, 2004, 4, 104-115.	2.8	49
127	Pathology of the gallbladder: a concise review. Current Diagnostic Pathology, 2004, 10, 304-317.	0.4	9
128	Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Human Pathology, 2004, 35, 357-366.	2.0	134
129	Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. American Journal of Surgery, 2004, 188, 171-175.	1.8	85
130	Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointestinal Endoscopy, 2004, 60, 68-75.	1.0	101
131	Palliative Therapie des Gallengangkarzinoms. Visceral Medicine, 2004, 20, 286-292.	1.3	0
132	Major Hepatic Resection for Hilar Cholangiocarcinoma. Archives of Surgery, 2004, 139, 514.	2.2	183
133	Intrahepatic Cholangiocarcinoma Associated with Central Calcification and Arterio-portal Shunt. Internal Medicine, 2005, 44, 825-828.	0.7	10



#	ARTICLE	IF	CITATIONS
134	Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. <i>European Journal of Cancer Prevention</i> , 2005, 14, 245-250.	1.3	41
135	The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies. <i>Clinical Biochemistry</i> , 2005, 38, 520-525.	1.9	9
136	Endoscopic Oncology. <i>Current Problems in Cancer</i> , 2005, 29, 39-112.	2.0	0
137	Photodynamic Therapy for Pancreatic and Biliary Tract Carcinoma. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 001-014.	0.4	29
138	Preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma. <i>Hpb</i> , 2005, 7, 252-253.	0.3	56
139	Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 415-420.	2.8	78
140	Review article: current management of primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 933-948.	3.7	71
141	Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. <i>BMC Cancer</i> , 2005, 5, 61.	2.6	27
142	Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. <i>Cancer</i> , 2005, 103, 1402-1407.	4.1	68
143	Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experience. <i>Liver Transplantation</i> , 2005, 11, 1412-1416.	2.4	132
144	Clinicopathological Factors Predicting Long-term Overall Survival after Hepatectomy for Peripheral Cholangiocarcinoma. <i>World Journal of Surgery</i> , 2005, 29, 894-898.	1.6	61
146	Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 171-181.	3.0	8
147	Cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 493-502.	0.8	10
148	Extended Hepatectomy for Intrahepatic Cholangiocellular Carcinoma (ICC). <i>Annals of Surgery</i> , 2005, 241, 134-143.	4.2	176
149	Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 68-73.	1.3	64
152	Mucin-producing cholangiocarcinoma: Clinical experience of 24 cases in 16 years. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 455-459.	1.5	15
153	Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 2332-2338.	1.6	297
154	Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1860-1866.	4.1	31

#	ARTICLE	IF	CITATIONS
155	History of photodynamic therapy in Great Britain. Photodiagnosis and Photodynamic Therapy, 2005, 2, 239-246.	2.6	11
156	Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology, 2005, 128, 620-626.	1.3	499
157	Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2005, 37, 269-274.	0.9	28
158	Cancers des voies biliaires. , 2006, , 179-194.		1
159	Preoperative Assessment of Resectability of Hepatic Hilar Cholangiocarcinoma: Combined CT and Cholangiography with Revised Criteria. Radiology, 2006, 239, 113-121.	7.3	200
160	Hepatic Resection in the Treatment of Hilar Cholangiocarcinoma. Advances in Surgery, 2006, 40, 159-171.	1.3	54
161	Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. British Journal of Cancer, 2006, 95, 848-852.	6.4	116
162	Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology, 2006, 45, 43-50.	3.7	289
163	Secretin receptors in the human liver: Expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 825-835.	3.7	41
164	Mortality at Ibn Sina surgical gastroenterology unit as predicted by POSSUM with brief literature review. Sudan Journal of Medical Sciences, 2006, 1, 20.	0.3	0
165	Angiogenesis in cholangiocellular carcinoma: Expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncology Reports, 2006, 15, 525.	2.6	38
166	Epistaxis packing. Postgraduate Medicine, 2006, 119, 77-82.	2.0	10
167	Cholestatic liver disease. Postgraduate Medicine, 2006, 119, 67-82.	2.0	2
168	Endoscopic palliation of cholangiocarcinoma. Current Opinion in Gastroenterology, 2006, 22, 551-560.	2.3	27
169	Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 999-1003.	2.8	36
170	Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma. Modern Pathology, 2006, 19, 772-779.	5.5	42
171	Clinicopathological Review of 61 Patients with Early Bile Duct Cancer. Clinical Oncology, 2006, 18, 669-677.	1.4	23
173	Aberrant promoter hypermethylation in biliary tract carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 296-305.	2.0	7

#	ARTICLE	IF	CITATIONS
174	Gallbladder cancer: surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 562-566.	2.0	29
175	Prevalence of pancreatic and biliary tract tumors in pancreas divisum. Journal of Gastroenterology, 2006, 41, 1088-1093.	5.1	35
176	Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. Journal of Cancer Research and Clinical Oncology, 2006, 132, 771-779.	2.5	15
178	Cancers of the biliary system. Gastroenterologie Clinique Et Biologique, 2006, 30, 62-74.	0.9	4
179	Detection of Human Aspartyl (Asparaginy) Beta-Hydroxylase and Homeobox B7 mRNA in Brush Cytology Specimens from Patients with Bile Duct Cancer. Endoscopy, 2006, 38, 604-609.	1.8	19
180	Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. Journal of the National Cancer Institute, 2006, 98, 873-875.	6.3	332
181	What Is the Current State of the Art Imaging for Detection and Staging of Cholangiocarcinoma?. Oncologist, 2006, 11, 913-922.	3.7	99
182	Is a Raised CA 19-9 Level Diagnostic for a Cholangiocarcinoma in Patients with No History of Sclerosing Cholangitis ?. Digestive Surgery, 2006, 23, 319-324.	1.2	18
183	Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Annals of Oncology, 2006, 17, vii68-vii72.	1.2	50
184	Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology, 2006, 17, vii73-vii77.	1.2	30
185	Cholangiocarcinoma and its management. Gut, 2007, 56, 1755-1756.	12.1	38
186	Chemotherapy with Gemcitabine and Oxaliplatin in Patients with Advanced Biliary Tract Cancer: A Single-Institution Experience. Oncology, 2007, 73, 311-315.	1.9	30
188	A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 843-851.	1.3	94
189	Response: Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. Journal of the National Cancer Institute, 2007, 99, 407-408.	6.3	2
190	Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma. Clinical Cancer Research, 2007, 13, 4795-4799.	7.0	87
191	Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. Journal of the National Cancer Institute, 2007, 99, 407-407.	6.3	15
192	Irinotecan With 5-FU/FA in Advanced Biliary Tract Adenocarcinomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 319-324.	1.3	41
193	Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. European Journal of Surgical Oncology, 2007, 33, 1025-1029.	1.0	66

#	ARTICLE	IF	CITATIONS
195	Hepatitis B Virus and Intrahepatic Cholangiocarcinoma. <i>Cancer Investigation</i> , 2007, 25, 55-58.	1.3	17
196	Emerging drugs for biliary cancer. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 571-589.	2.4	11
197	Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. <i>Digestive and Liver Disease</i> , 2007, 39, 60-69.	0.9	53
198	Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan®- and Foslip®-based photodynamic treatment in human biliary tract cancer cell lines. <i>Photochemical and Photobiological Sciences</i> , 2007, 6, 619-627.	2.9	85
199	Malignant Biliary Obstruction: Clinical Outcome of Endoscopic Intervention - An Experience of Tertiary Centers. <i>Journal of Bangladesh College of Physicians &amp; Surgeons</i> , 2007, 24, 61-68.	0.1	0
200	Current surgical treatment for bile duct cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 1505.	3.3	112
201	Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China. <i>International Journal of Cancer</i> , 2007, 120, 1981-1985.	5.1	32
202	Hepatitis B and C virus infection and the risk of biliary tract cancer: A population-based study in China. <i>International Journal of Cancer</i> , 2008, 122, 1849-1853.	5.1	72
203	Serum lipid levels and the risk of biliary tract cancers and biliary stones: A population-based study in China. <i>International Journal of Cancer</i> , 2008, 122, 2322-2329.	5.1	76
204	Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. <i>Hepatology</i> , 2008, 47, 90-96.	7.3	119
205	Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. <i>Journal of Surgical Oncology</i> , 2007, 96, 8-13.	1.7	83
206	Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; Drainage vs. (direct) Operation (DROP-trial). <i>BMC Surgery</i> , 2007, 7, 3.	1.3	64
207	Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. <i>British Journal of Cancer</i> , 2007, 96, 896-902.	6.4	436
208	Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 389-394.	2.8	22
209	Restoration of RUNX3 enhances transforming growth factor- $\beta$ -dependent p21 expression in a biliary tract cancer cell line. <i>Cancer Science</i> , 2007, 98, 838-843.	3.9	16
210	Mutations in Bile Salt Export Pump (ABCB11) in Two Children with Progressive Familial Intrahepatic Cholestasis and Cholangiocarcinoma. <i>Journal of Pediatrics</i> , 2007, 150, 556-559.	1.8	129
211	Cancer of the Gallbladder and Extrahepatic Bile Ducts. <i>Current Problems in Surgery</i> , 2007, 44, 396-482.	1.1	29
212	Bile Duct Cyst as Precursor to Biliary Tract Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 1200-1211.	1.5	83

#	ARTICLE	IF	CITATIONS
213	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. <i>Annals of Surgical Oncology</i> , 2007, 14, 3202-3209.	1.5	68
214	Liver transplantation for non-hepatocellular carcinoma malignancy. <i>Hpb</i> , 2007, 9, 98-103.	0.3	25
216	Pancreatic and Duodenal Invasion in Distal Bile Duct Cancer: Paradox in the Tumor Classification of the American Joint Committee on Cancer. <i>World Journal of Surgery</i> , 2007, 31, 2008-2015.	1.6	51
217	Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 47-52.	2.3	34
218	Animal PET for Thioacetamide-Induced Rat Cholangiocarcinoma: A Novel and Reliable Platform. <i>Molecular Imaging and Biology</i> , 2008, 10, 209-216.	2.6	23
219	Unusual Segmental Stricture of the Lower Common Bile Duct Mimicking Bile Duct Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 199-201.	1.7	1
220	Diagnosis and management of cholangiocarcinoma. <i>Current Gastroenterology Reports</i> , 2008, 10, 43-52.	2.5	30
221	Cholangiocarcinoma: Expanding the Spectrum of Risk Factors. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 114-117.	1.3	8
222	Flowcharts for the management of biliary tract and ampullary carcinomas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 7-14.	2.0	20
223	Diagnosis of biliary tract and ampullary carcinomas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 31-40.	2.0	43
224	Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. <i>Journal of Gastroenterology</i> , 2008, 43, 959-966.	5.1	47
225	MR imaging findings of early bile duct cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 1466-1475.	3.4	20
226	Hepatectomy of segment 4a and 5 combined with extrahepatic bile duct resection for T2 and T3 gallbladder carcinoma. <i>Journal of Surgical Oncology</i> , 2008, 97, 498-502.	1.7	48
227	Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres. <i>Cancer</i> , 2008, 113, 2119-2128.	4.1	182
228	Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. <i>Hepatology</i> , 2008, 48, 308-321.	7.3	614
229	Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 600-608.	1.5	193
230	Clinical results of intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of biliary tract cancer. <i>Hpb</i> , 2008, 10, 144-147.	0.3	1
231	The role of chemotherapy in biliary tract carcinoma. <i>Hpb</i> , 2008, 10, 164-167.	0.3	27

#	ARTICLE	IF	CITATIONS
232	Staging of extrahepatic cholangiocarcinoma. <i>European Radiology</i> , 2008, 18, 2182-2195.	4.5	56
233	Preoperative staging of biliary carcinoma using 18F-fluorodeoxyglucose PET: prospective comparison with PET+CT, MDCT and histopathology. <i>European Radiology</i> , 2008, 18, 2841-2847.	4.5	44
234	Management of combined hepatocellular and cholangiocarcinoma. <i>International Journal of Clinical Practice</i> , 2008, 62, 1271-1278.	1.7	130
235	Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. <i>British Journal of Cancer</i> , 2008, 99, 862-867.	6.4	158
236	Usefulness of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 759-765.	2.8	61
238	Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2008, 143, 769-777.	1.9	94
239	A brief overview of photodynamic therapy in Europe. <i>Photodiagnosis and Photodynamic Therapy</i> , 2008, 5, 103-111.	2.6	65
240	Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer. <i>Gastroenterology</i> , 2008, 135, 1358-1368.e4.	1.3	424
241	Malignant Biliary Obstruction: Hilar. , 2008, , 299-311.		0
242	Stones from cancerous and benign gallbladders are different: A proton nuclear magnetic resonance spectroscopy study. <i>Hepatology Research</i> , 2008, 38, 997-1005.	3.4	19
243	Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2008, 12, 131-150.	2.1	212
244	Unresectable Cholangiocarcinoma: Comparison of Survival in Biliary Stenting Alone Versus Stenting With Photodynamic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 290-297.	4.4	184
245	Differential Membrane Proteomics Using <sup>18</sup> O-Labeling To Identify Biomarkers for Cholangiocarcinoma. <i>Journal of Proteome Research</i> , 2008, 7, 4670-4677.	3.7	43
246	Primary Cancer of the Liver and Biliary Duct. <i>PET Clinics</i> , 2008, 3, 169-186.	3.0	2
247	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2339-2347.	4.1	38
248	Clinical Role of <sup>18</sup> F-FDG PET-CT in Suspected and Potentially Operable Cholangiocarcinoma: A Prospective Study Compared With Conventional Imaging. <i>American Journal of Gastroenterology</i> , 2008, 103, 1145-1151.	0.4	205
249	Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , 2008, 26, 3702-3708.	1.6	72
250	Polymorphisms of Genes in the Lipid Metabolism Pathway and Risk of Biliary Tract Cancers and Stones: A Population-Based Case-Control Study in Shanghai, China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 525-534.	2.5	33

#	ARTICLE	IF	CITATIONS
251	Clinical Significance of Cell Cycle and Apoptosis-Related Markers in Biliary Tract Cancer. American Journal of Clinical Pathology, 2008, 130, 780-786.	0.7	45
252	Cholangiocarcinoma: Current and Novel Imaging Techniques. Radiographics, 2008, 28, 1263-1287.	3.3	135
253	Chemotherapy with Gemcitabine in Advanced Biliary Tract Carcinoma. Reviews on Recent Clinical Trials, 2008, 3, 70-78.	0.8	6
254	Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. European Journal of Gastroenterology and Hepatology, 2008, 20, 1115-1117.	1.6	7
255	Biliary Malignancy. Journal of Computer Assisted Tomography, 2008, 32, 362-368.	0.9	19
256	Plastic Versus Self-expanding Metallic Stents for Malignant Hilar Biliary Obstruction. Journal of Clinical Gastroenterology, 2008, 42, 1040-1046.	2.2	179
257	Primary sclerosing cholangitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 689-698.	1.7	73
258	Photodynamic Therapy: Palliation and Endoscopic Technique in Cholangiocellular Carcinoma. Frontiers of Gastrointestinal Research, 2009, , 423-429.	0.1	3
259	Staging of cholangiocarcinoma. , 0, , 160-176.		0
260	Epidemiology of hepatocellular carcinoma and cholangiocarcinoma. , 0, , 1-9.		1
261	Radiological diagnosis of cholangiocarcinoma. , 0, , 136-159.		1
262	Cancer des voies biliaires : les tables de la loi. Les recommandations du Thésaurus National de Cancérologie Digestive. Cancéro Digest, 2009, 1, 112.	0.0	0
263	Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 417-423.	2.5	24
264	Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers. Oncology, 2009, 76, 254-261.	1.9	41
265	Benign and Malignant Tumors of the Gallbladder and Extrahepatic Biliary Tract. , 2009, , 845-875.		23
266	Epidemiology of biliary tract cancers: an update. Annals of Oncology, 2009, 20, 146-159.	1.2	222
267	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Molecular Cancer Therapeutics, 2009, 8, 1547-1556.	4.1	28
268	Biliary cancer: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv46-iv48.	1.2	17



#	ARTICLE	IF	CITATIONS
269	Operations for Intrahepatic Cholangiocarcinoma: Single-Institution Experience of 158 Patients. Journal of the American College of Surgeons, 2009, 208, 218-228.	0.5	189
270	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009, 49, 1595-1601.	7.3	247
271	Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth. Journal of Surgical Oncology, 2009, 99, 161-165.	1.7	25
274	Preoperative Biliary Drainage in Patients with Obstructive Jaundice: History and Current Status. Journal of Gastrointestinal Surgery, 2009, 13, 814-820.	1.7	152
275	Vascular involvement in periampullary tumors: MDCT, EUS, and CDU. Abdominal Imaging, 2009, 34, 514-522.	2.0	9
276	Incidental Gallbladder Carcinoma Diagnosed During or After Laparoscopic Cholecystectomy. World Journal of Surgery, 2009, 33, 2651-2656.	1.6	57
277	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemotherapy and Pharmacology, 2009, 65, 73-78.	2.3	13
278	A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucovorin for advanced biliary tract carcinoma. Cancer Chemotherapy and Pharmacology, 2009, 65, 151-157.	2.3	6
279	Primary patency of percutaneously inserted self-expanding metallic stents in patients with malignant biliary obstruction. Hpb, 2009, 11, 358-363.	0.3	18
280	Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochemical and Photobiological Sciences, 2009, 8, 23-30.	2.9	29
281	Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Biochemical and Biophysical Research Communications, 2009, 385, 251-256.	2.1	22
282	Cholangiocarcinoma: Improving biliary drainage with PDT. Photodiagnosis and Photodynamic Therapy, 2009, 6, 82-83.	2.6	1
283	CD30. , 2008, , 544-544.		0
284	Radical Resection of Biliary Tract Cancers and the Role of Extended Lymphadenectomy. Surgical Oncology Clinics of North America, 2009, 18, 339-359.	1.5	2
285	CD15. , 2008, , 540-540.		0
286	Catastrophe Promoter. , 2008, , 526-526.		0
287	Ultrasensitive Detection of KRAS2 Mutations in Bile and Serum from Patients with Biliary Tract Carcinoma Using LigAmp Technology. Journal of Molecular Diagnostics, 2009, 11, 583-589.	2.8	8
288	Hematoporphyrin derivative-mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma <i>in vitro</i> and <i>in vivo</i> . Hepatology Research, 2009, 39, 1190-1197.	3.4	11



#	ARTICLE	IF	CITATIONS
290	Multidisciplinary Approach to Tumors of the Pancreas and Biliary Tree. Surgical Clinics of North America, 2009, 89, 115-131.	1.5	11
291	Transplantation for Cholangiocarcinoma: When and for Whom?. Surgical Oncology Clinics of North America, 2009, 18, 325-337.	1.5	66
292	Extended Liver Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgery, 2009, 249, 303-309.	4.2	117
293	Retrospective Analysis of Histopathologic Prognostic Factors After Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancer Journal (Sudbury, Mass ), 2009, 15, 257-261.	2.0	28
294	Photodynamic therapy for pancreatic and biliary tract carcinoma. , 2009, , .		0
295	Intervals between Symptom Onset and Clinical Presentation in Cancer Patients. Internal Medicine, 2009, 48, 899-905.	0.7	16
296	Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. International Journal of Oncology, 2009, 36, .	3.3	12
298	Increasing Incidence of Intrahepatic Cholangiocarcinoma and its Relationship to Chronic Viral Hepatitis. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 423-427.	4.9	45
299	Molecular Targeted Therapy of Biliary Tract Cancer – Results of the First Clinical Studies. Current Drug Targets, 2010, 11, 834-850.	2.1	36
301	Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemotherapy and Pharmacology, 2010, 65, 641-647.	2.3	76
302	Percutaneous Treatment of Malignant Jaundice Due to Extrahepatic Cholangiocarcinoma: Covered Viabil Stent Versus Uncovered Wallstents. CardioVascular and Interventional Radiology, 2010, 33, 97-106.	2.0	96
304	Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. Journal of Gastroenterology, 2010, 45, 560-566.	5.1	123
305	Occupational exposure to pesticides and bile tract carcinoma in men: results from a European multicenter case–control study. Cancer Causes and Control, 2010, 21, 1493-1502.	1.8	5
306	The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Molecular Biology Reports, 2010, 37, 2693-2701.	2.3	24
307	The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 2010, 28, 854-858.	2.6	5
308	Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer, 2010, 10, 564.	2.6	18
309	Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer, 2010, 116, 400-405.	4.1	21
310	The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer, 2010, 116, 2208-2214.	4.1	35

#	ARTICLE	IF	CITATIONS
311	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010, 51, 2020-2029.	7.3	268
312	A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. <i>Hepatology</i> , 2010, 52, 550-561.	7.3	57
313	Cytoplasmic overexpression with membrane accentuation of stratifin in intrahepatic mass-forming cholangiocarcinoma after hepatectomy: Correlation with clinicopathologic features and patient survival. <i>Journal of Surgical Oncology</i> , 2010, 102, 608-614.	1.7	9
314	Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. <i>Liver Transplantation</i> , 2010, 16, 930-942.	2.4	55
315	In-hospital mortality after resection of biliary tract cancer in the United States. <i>Hpb</i> , 2010, 12, 62-67.	0.3	10
316	Epidemiology of cholangiocarcinoma: An update focusing on risk factors. <i>Cancer Science</i> , 2010, 101, 579-585.	3.9	385
317	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. <i>British Journal of Cancer</i> , 2010, 102, 68-72.	6.4	197
318	Comparison of Serum Tumor Markers for Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. <i>American Surgeon</i> , 2010, 76, 1210-1213.	0.8	62
319	Therapeutic effect of photodynamic therapy using hematoporphyrin monomethyl ether (HMME) on human cholangiocarcinoma cell line QBC939. <i>Neoplasma</i> , 2010, 57, 79-85.	1.6	12
320	Ictères néoplasiques: pour ou contre le drainage biliaire préopératoire?. <i>Cancéro Digest</i> , 2010, , .	0.0	0
321	Descriptive Epidemiology of Cholangiocarcinoma and Clonorchiasis in Korea. <i>Journal of Korean Medical Science</i> , 2010, 25, 1011.	2.5	102
322	Apoptotic activity of caged xanthenes from <i>Garcinia hanburyi</i> in cholangiocarcinoma cell lines. <i>World Journal of Gastroenterology</i> , 2010, 16, 2235.	3.3	30
323	Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma. <i>Chemotherapy</i> , 2010, 56, 234-238.	1.6	15
324	Phase II Trial of Gemcitabine Combined with 5-fluorouracil and Cisplatin (GFP) Chemotherapy in Patients with Advanced Biliary Tree Cancers. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 24-28.	1.3	22
325	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v65-v69.	1.2	60
326	Kinetics of Liver Volume Changes in the First Year After Portal Vein Embolization. <i>Archives of Surgery</i> , 2010, 145, 351.	2.2	27
327	Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. <i>World Journal of Gastrointestinal Endoscopy</i> , 2010, 2, 357.	1.2	16
328	Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. <i>Experimental and Molecular Medicine</i> , 2010, 42, 787.	7.7	27

#	ARTICLE	IF	CITATIONS
329	Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. Journal of Clinical Oncology, 2010, 28, 3491-3497.	1.6	246
330	Recent advances in the regulation of cholangiocarcinoma growth. American Journal of Physiology - Renal Physiology, 2010, 299, G1-G9.	3.4	24
331	Magnetic Resonance Imaging of Biliary Tumors. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 477-496.	1.1	14
332	Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. International Journal of Oncology, 2010, 37, .	3.3	4
333	Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointestinal Endoscopy, 2010, 72, 728-735.	1.0	260
335	A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. Journal of Hepatology, 2010, 52, 228-233.	3.7	88
337	Carcinoid tumor of the extrahepatic bile ducts: Sonographic, cholangiographic, and MDCT features. European Journal of Radiology Extra, 2010, 73, e89-e92.	0.1	0
338	Preoperative Biliary Drainage for Cancer of the Head of the Pancreas. New England Journal of Medicine, 2010, 362, 129-137.	27.0	921
339	Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochemical and Photobiological Sciences, 2010, 9, 734-743.	2.9	31
340	Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomarkers in Medicine, 2010, 4, 299-314.	1.4	38
341	Perihilar cholangiocarcinoma, the need for a new staging system. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 697-698.	1.5	7
342	CD30. , 2011, , 697-697.		0
343	CHI3L1. , 2011, , 796-796.		0
344	Gastrointestinal Oncology. , 2011, , .		2
346	Over-expression of human carcinoma-associated antigen in intrahepatic cholangiocellular carcinoma. Biochemical and Biophysical Research Communications, 2011, 405, 325-332.	2.1	3
347	Targeting <sc>PDGFR</sc> in Cholangiocarcinoma. Liver International, 2012, 32, 400-409.	3.9	41
348	Trends in the incidence and management of biliary tract cancer: A French population-based study. Journal of Hepatology, 2011, 54, 306-310.	3.7	63
349	Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma. Hepatology Research, 2011, 41, 64-70.	3.4	7

#	ARTICLE	IF	CITATIONS
350	Calcium-Binding Proteins. , 2011, , 591-595.		127
351	Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. Journal of Clinical and Experimental Hepatology, 2011, 1, 6-12.	0.9	48
352	Error in Author Name in: In Reply to: The True Cost of Operating Room Time. Archives of Surgery, 2011, 146, 1184.	2.2	0
353	Clinical Parameters Predicting Survival Duration after Hepatectomy for Intrahepatic Cholangiocarcinoma. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 603-608.	1.7	19
354	Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma. PLoS ONE, 2011, 6, e15640.	2.5	266
355	Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis. Nuclear Medicine Communications, 2011, 32, 252-259.	1.1	3
356	The Value of F-18 FDG PET in Patients With Primary Sclerosing Cholangitis and Cholangiocarcinoma Using Visual and Semiquantitative Analysis. Clinical Nuclear Medicine, 2011, 36, 879-883.	1.3	30
357	Markers of bile duct tumors. World Journal of Gastrointestinal Oncology, 2011, 3, 49.	2.0	31
358	Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis. Cancer Science, 2011, 102, 776-783.	3.9	13
359	The role of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma. Surgical Oncology, 2011, 20, e10-e17.	1.6	21
360	A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Journal of the American College of Surgeons, 2011, 213, S133.	0.5	1
361	Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. Journal of Zhejiang University: Science B, 2011, 12, 256-263.	2.8	20
362	Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Molecular Biology Reports, 2011, 38, 1769-1775.	2.3	19
363	Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Molecular Biology Reports, 2011, 38, 3075-3082.	2.3	16
364	Prognostic value of $^{18}\text{F}$ -fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 39-46.	2.6	32
365	Recent developments in the diagnosis and treatment of bile duct cysts: a review. European Surgery - Acta Chirurgica Austriaca, 2011, 43, 249-254.	0.7	0
366	Stereotactic Radiofrequency Ablation. CardioVascular and Interventional Radiology, 2011, 34, 852-856.	2.0	57
367	Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 379-388.	2.3	24

#	ARTICLE	IF	CITATIONS
368	Slug inhibition upregulates radiation-induced PUMA activity leading to apoptosis in cholangiocarcinomas. <i>Medical Oncology</i> , 2011, 28, 301-309.	2.5	16
369	Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it. <i>Clinical and Translational Oncology</i> , 2011, 13, 25-33.	2.4	35
370	Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. <i>Hepatology</i> , 2011, 53, 640-648.	7.3	48
371	New staging system and a registry for perihilar cholangiocarcinoma. <i>Hepatology</i> , 2011, 53, 1363-1371.	7.3	252
372	Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. <i>Hepatology</i> , 2011, 54, 2076-2088.	7.3	134
373	PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. <i>International Journal of Cancer</i> , 2011, 129, 34-44.	5.1	47
374	Emerging pharmacotherapeutic strategies for cholangiocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1865-1874.	1.8	8
375	Choledochal Cyst and Associated Malignant Tumors in Adults. <i>Archives of Surgery</i> , 2011, 146, 1178.	2.2	114
376	A Phase II Study of Outpatient Biweekly Gemcitabine-Oxaliplatin in Advanced Biliary Tract Carcinomas. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 217-224.	1.3	4
377	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi40-vi44.	1.2	72
378	Genetic Factors in the Pathogenesis of Cholangiocarcinoma. <i>Digestive Diseases</i> , 2011, 29, 93-97.	1.9	29
379	A combination of serum leucine-rich $\alpha_2$ -glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. <i>British Journal of Cancer</i> , 2011, 105, 1370-1378.	6.4	63
380	Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 589-600.	2.4	10
381	Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study. <i>Onkologie</i> , 2011, 34, 469-470.	0.8	25
382	RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via Upregulating PUMA. <i>International Journal of Molecular Sciences</i> , 2011, 12, 385-400.	4.1	24
383	Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. <i>Acta Oncologica</i> , 2012, 51, 860-866.	1.8	33
384	Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. <i>British Journal of Radiology</i> , 2012, 85, 1078-1084.	2.2	71
385	Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. <i>British Journal of Radiology</i> , 2012, 85, 1029-1037.	2.2	51

#	ARTICLE	IF	CITATIONS
387	Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer. <i>Oncology</i> , 2012, 83, 83-90.	1.9	46
388	Ultrasound of the liver, biliary tract, and pancreas. , 2012, , 204-231.e3.		2
389	Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. <i>Annals of Oncology</i> , 2012, 23, 2341-2346.	1.2	89
390	Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study. <i>Chemotherapy</i> , 2012, 58, 225-232.	1.6	18
391	Biliary Tract Cancers in Olmsted County, Minnesota, 1976â€“2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.4	68
392	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. <i>Oncology</i> , 2012, 82, 75-82.	1.9	7
393	Role of 18F-FDG PET/CT in Detecting Recurrent Gallbladder Carcinoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, 431-435.	1.3	36
394	Association of stem cell marker expression pattern and survival in human biliary tract cancer. <i>International Journal of Oncology</i> , 2012, 41, 511-522.	3.3	12
395	CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. <i>Oncology Reports</i> , 2012, 27, 1266-1276.	2.6	34
396	Biliary Excretion of Curcumin Is Mediated by Multidrug Resistance-Associated Protein 2. <i>Biological and Pharmaceutical Bulletin</i> , 2012, 35, 777-780.	1.4	10
397	Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1934-1940.	1.6	602
398	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. <i>Investigational New Drugs</i> , 2012, 30, 2148-2160.	2.6	15
399	Clinical outcome in patients with hilar malignant strictures type II Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 209-214.	1.3	28
400	Role of the stromal-derived factor-1 (SDF-1)â€“CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 57, 813-820.	3.7	82
401	Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. <i>European Journal of Cancer</i> , 2012, 48, 990-996.	2.8	50
402	A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study. <i>European Journal of Cancer</i> , 2012, 48, 196-201.	2.8	110
403	MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. <i>Gene</i> , 2012, 493, 44-51.	2.2	85
404	Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years. <i>Chemotherapy</i> , 2012, 58, 134-141.	1.6	20

#	ARTICLE	IF	CITATIONS
405	Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. Photodiagnosis and Photodynamic Therapy, 2012, 9, 287-292.	2.6	22
406	Surgical Management Trends for Cholangiocarcinoma in the USA 1998â€“2009. Journal of Gastrointestinal Surgery, 2012, 16, 2225-2232.	1.7	10
407	Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. Journal of Gastrointestinal Cancer, 2012, 43, 396-404.	1.3	24
408	Cholangiocarcinoma Treatment. Current Gastroenterology Reports, 2012, 14, 528-533.	2.5	8
409	Stereotactic Radiofrequency Ablation of Unresectable Intrahepatic Cholangiocarcinomas: A Retrospective Study. CardioVascular and Interventional Radiology, 2012, 35, 1074-1082.	2.0	64
410	Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 349-359.	1.3	35
411	Pancreas and liver. , 0, , 242-266.		0
412	NMR Spectroscopy-Based Metabolic Profiling for Detecting Hepatobiliary Diseases. ACS Symposium Series, 2012, , 407-415.	0.5	0
413	Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transplantation, 2012, 18, 594-601.	2.4	37
414	Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. International Journal of Cancer, 2012, 131, 733-740.	5.1	123
416	Cancer of the bile ducts. , 2012, , 789-800.e3.		0
417	Expression of Matrix Metalloproteinase-7 is an Unfavorable Prognostic Factor in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 842-848.	1.7	28
418	Risk Factors for Gallbladder Cancer and Cholangiocarcinoma: Similarities, Differences and Updates. Journal of Gastrointestinal Cancer, 2012, 43, 137-147.	1.3	58
419	A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures. Cancer Chemotherapy and Pharmacology, 2012, 69, 1127-1133.	2.3	7
420	Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma. Surgery Today, 2012, 42, 565-569.	1.5	3
421	Gallbladder cancer: Can newer insights improve the outcome?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 642-653.	2.8	111
422	Photodynamic Therapy for Unresectable Cholangiocarcinoma. Digestive Diseases and Sciences, 2012, 57, 274-283.	2.3	31
423	Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. International Journal of Cancer, 2013, 132, 645-657.	5.1	158



#	ARTICLE	IF	CITATIONS
424	Excision repair cross-complementing gene <sup>1</sup> , ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter <sup>4</sup> expression and prognostic value in biliary tract malignancy. <i>Cancer</i> , 2013, 119, 454-462.	4.1	28
425	Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. <i>Tumor Biology</i> , 2013, 34, 3519-3528.	1.8	34
426	Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection. <i>Abdominal Imaging</i> , 2013, 38, 1334-1350.	2.0	51
427	The risk factors and diagnosis of cholangiocarcinoma. <i>Hepatology International</i> , 2013, 7, 377-393.	4.2	13
428	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1188-1193.	3.7	110
429	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. <i>Radiation Oncology</i> , 2013, 8, 292.	2.7	57
431	Positron emission tomography in malignancies of the liver, pancreas and biliary tract – indications and potential pitfalls. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 259-265.	1.5	6
432	A polysaccharide from the fungi of <i>Huair</i> exhibits anti-tumor potential and immunomodulatory effects. <i>Carbohydrate Polymers</i> , 2013, 92, 577-582.	10.2	81
433	Second-line therapy in advanced biliary tract cancer: What should be the standard?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 368-374.	4.4	18
434	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 329-335.	2.8	104
436	Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 423-429.	2.4	1
437	Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin. <i>Photochemical and Photobiological Sciences</i> , 2013, 12, 1065-1073.	2.9	26
438	Carcinoma of the gallbladder: Patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. <i>European Journal of Surgical Oncology</i> , 2013, 39, 548-553.	1.0	75
439	Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. <i>Hepatology</i> , 2013, 58, 1362-1374.	7.3	37
440	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. <i>Oncology Letters</i> , 2013, 6, 1487-1491.	1.8	21
441	Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients. <i>Endoscopy</i> , 2013, 45, 883-889.	1.8	85
442	State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 425-431.	2.4	24
443	Effect of CO <sub>2</sub> cholangiography on post-ERCP cholangitis in patients with unresectable malignant hilar obstruction – a prospective, randomized controlled study. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 758-763.	1.5	15



#	ARTICLE	IF	CITATIONS
444	FOLFOX-4 Regimen or Single-agent Gemcitabine as First-line Chemotherapy in Advanced Biliary Tract Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 466-471.	1.3	17
445	Efficacy of gemcitabine plus platinum agents for biliary tract cancers. <i>Anti-Cancer Drugs</i> , 2013, 24, 871-877.	1.4	34
446	Chemotherapy for cholangiocarcinoma: An update. <i>World Journal of Gastrointestinal Oncology</i> , 2013, 5, 171.	2.0	122
447	Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study. <i>Chemotherapy</i> , 2013, 59, 232-238.	1.6	28
448	Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy. <i>Molecular and Clinical Oncology</i> , 2013, 1, 987-994.	1.0	5
449	Role of biliary tract cytology in the evaluation of extrahepatic cholestatic jaundice. <i>Journal of Cytology</i> , 2013, 30, 162.	0.6	7
450	MicroRNA Function in Human Diseases. <i>Medical Epigenetics</i> , 2013, 1, 106-115.	262.3	16
451	Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. <i>Annals of Oncology</i> , 2013, 24, 543-553.	1.2	98
452	Role of diffusion-weighted magnetic resonance imaging in the diagnosis of gallbladder cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 127-137.	3.4	39
453	Telomeres and telomere dynamics: relevance to cancers of the GI tract. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 733-748.	3.0	26
454	cDNA microarray profiling of rat cholangiocarcinoma induced by thioacetamide. <i>Molecular Medicine Reports</i> , 2013, 8, 350-360.	2.4	10
455	Presentation and Management of <i>Candida</i> -Associated Vasculitis With Gastrointestinal Involvement in a Pediatric Patient. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, e46-8.	1.8	2
456	The Clinical Value of Dual-Point 18F-FDG PET/CT for Differentiating Extrahepatic Cholangiocarcinoma From Benign Disease. <i>Clinical Nuclear Medicine</i> , 2013, 38, e106-e111.	1.3	31
457	Raised Serum Aminotransferase Levels and Muscle Pseudohypertrophy Caused by Hypothyroidism. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, e48-9.	1.8	3
458	Rectal Bleeding and Hypertensive Colopathy in May-Thurner Syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, e42-3.	1.8	1
459	Cholangiocarcinoma in a Young Woman With Perinatally Acquired HIV. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, e43-6.	1.8	0
460	New and emerging treatment options for biliary tract cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 1545.	2.0	17
461	Down-Regulation of Gab1 Inhibits Cell Proliferation and Migration in Hilar Cholangiocarcinoma. <i>PLoS ONE</i> , 2013, 8, e81347.	2.5	26

#	ARTICLE	IF	CITATIONS
462	Serum estrogen level and lipid profile in Gall stone and Gallbladder cancer: a case control study. International Journal of Biomedical Research, 2013, 4, 415.	0.1	0
463	Gemcitabine, Oxaliplatin and Bevacizumab in patients with biliary tract cancers. Journal of Solid Tumors, 2013, 3, .	0.1	1
464	Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Gallbladder Cancer: A Retrospective Review. American Surgeon, 2014, 80, 710-713.	0.8	10
465	Analysis of gallbladder polypoid lesion size as an indication of the risk of gallbladder cancer. Korean Journal of Hepato-biliary-pancreatic Surgery, 2014, 18, 9.	1.0	8
466	JNK Contributes to the Tumorigenic Potential of Human Cholangiocarcinoma Cells through the mTOR Pathway Regulated GRP78 Induction. PLoS ONE, 2014, 9, e90388.	2.5	16
467	The Real-Time Dynamic Monitoring of microRNA Function in Cholangiocarcinoma. PLoS ONE, 2014, 9, e99431.	2.5	7
468	Sociodemographic Trends in the Incidence of Pancreatic and Biliary Tract Cancer in UK Primary Care. PLoS ONE, 2014, 9, e108498.	2.5	6
469	Y-Shaped Bilateral Self-Expandable Metallic Stent Placement for Malignant Hilar Biliary Obstruction: Data from a Referral Center for Palliative Care. Scientific World Journal, The, 2014, 2014, 1-5.	2.1	3
470	Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Molecular and Cellular Biochemistry, 2014, 396, 257-268.	3.1	20
471	Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. Chemotherapy, 2014, 60, 13-23.	1.6	40
472	Current state of nonsurgical therapies for cholangiocarcinoma. Hepatic Oncology, 2014, 1, 135-142.	4.2	0
473	Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts. Oncology Letters, 2014, 8, 1919-1924.	1.8	14
474	MicroRNAs Associated with the Efficacy of Photodynamic Therapy in Biliary Tract Cancer Cell Lines. International Journal of Molecular Sciences, 2014, 15, 20134-20157.	4.1	18
475	Palliative Treatment for Advanced Biliary Adenocarcinomas With Combination Dimethyl Sulfoxideâ€“Sodium Bicarbonate Infusion and S-Adenosyl-L-Methionine. Journal of Pain and Palliative Care Pharmacotherapy, 2014, 28, 206-211.	0.8	9
476	A caseâ€“control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open, 2014, 4, e005720.	1.9	68
477	Administration of Gemcitabine for Metastatic Adenocarcinoma during Pregnancy: A Case Report and Review of the Literature. AJP Reports, 2014, 4, 017-022.	0.7	12
478	Mutational landscape of intrahepatic cholangiocarcinoma. Nature Communications, 2014, 5, 5696.	12.8	314
479	<sc>FISH</sc>ing for pancreatobiliary tract malignancy in endoscopic brushings enhances the sensitivity of routine cytology. Cytopathology, 2014, 25, 288-301.	0.7	24

#	ARTICLE	IF	CITATIONS
480	Clinicopathological and prognostic significances of <scp>EGFR</scp>, <scp>KRAS</scp> and <scp>BRAF</scp> mutations in biliary tract carcinomas in <scp>Taiwan</scp>. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1119-1125.	2.8	28
481	Incidence and mortality trends for biliary tract cancers in Austria. Liver International, 2014, 34, 1102-1108.	3.9	31
482	Implication of Lymph Node Metastasis Detected on 18F-FDG PET/CT for Surgical Planning in Patients With Peripheral Intrahepatic Cholangiocarcinoma. Clinical Nuclear Medicine, 2014, 39, 1-7.	1.3	40
483	Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?. Medicine (United States), 2014, 93, e305.	1.0	2
484	Endoscopic treatment options for cholangiocarcinomas. Expert Review of Anticancer Therapy, 2014, 14, 407-418.	2.4	12
485	Biliary Proliferative Lesions in the Sprague-Dawley Rat. Toxicologic Pathology, 2014, 42, 844-854.	1.8	18
486	Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 403-408.	2.8	11
487	Induction of apoptosis in cholangiocarcinoma by an andrographolide analogue is mediated through topoisomerase II alpha inhibition. European Journal of Pharmacology, 2014, 723, 148-155.	3.5	29
488	Endoscopic stenting in bile duct cancer increases liver volume. Gastrointestinal Endoscopy, 2014, 80, 447-455.	1.0	5
489	A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. International Journal of Clinical Oncology, 2014, 19, 485-489.	2.2	35
490	Prediction of the Postoperative Prognosis of Intrahepatic Cholangiocarcinoma (ICC): Importance of Preoperatively-Determined Anatomic Invasion Level and Number of Tumors. Digestive Diseases and Sciences, 2014, 59, 201-213.	2.3	43
491	Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro. Tumor Biology, 2014, 35, 3103-3112.	1.8	12
492	Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 854-860.	2.4	168
494	A novel serum marker for biliary tract cancer: Diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC). Surgery, 2014, 155, 633-639.	1.9	32
495	A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers. Clinical Colorectal Cancer, 2014, 13, 81-86.	2.3	25
496	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	6.4	69
497	Hilar Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2014, 23, 247-263.	1.5	48
498	Intrahepatic Cholangiocarcinoma. Surgical Oncology Clinics of North America, 2014, 23, 231-246.	1.5	67

#	ARTICLE	IF	CITATIONS
499	A Differential MicroRNA Profile Distinguishes Cholangiocarcinoma from Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 133-138.	1.5	44
500	Radiology Illustrated: Hepatobiliary and Pancreatic Radiology. <i>Radiology Illustrated</i> , 2014, , .	0.0	3
501	The Treatment of Cholangiocarcinoma: a Hepatologist's Perspective. <i>Current Gastroenterology Reports</i> , 2014, 16, 412.	2.5	11
502	Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development. <i>Molecular Cancer Research</i> , 2014, 12, 91-100.	3.4	65
503	Diagnosis and treatment of cholangiocarcinoma: A consensus from surgical specialists of China. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014, 34, 469-475.	1.0	17
504	Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning. <i>BioMedical Engineering OnLine</i> , 2014, 13, 118.	2.7	7
505	Efficacy of Hepatic Arterial Infusion Chemotherapy Using 5-Fluorouracil and Systemic Pegylated Interferon $\alpha$ -2b for Advanced Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 3638-3645.	1.5	19
506	Prognostic and predictive value of metabolic tumor volume on 18F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib. <i>Medical Oncology</i> , 2014, 31, 23.	2.5	9
508	Near-infrared fluorescence cholangiopancreatography: initial clinical feasibility results. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 664-668.	1.0	12
509	Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 54-60.	2.1	83
510	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 819-828.	10.7	345
511	Expression of Anterior Gradient 2 Is Decreased with the Progression of Human Biliary Tract Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2014, 234, 83-88.	1.2	9
512	Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. <i>Viszeralmedizin</i> , 2014, 30, 238-243.	0.0	7
513	Hepatitis B and C Virus Infection is a Risk Factor for the Development of Cholangiocarcinoma. <i>Internal Medicine</i> , 2014, 53, 651-654.	0.7	49
514	Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor- $\kappa$ B pathways in human cholangiocarcinomas both in vitro and in vivo. <i>Oncology Reports</i> , 2014, 31, 2063-2070.	2.6	64
515	Hilar Cholangiocarcinoma: expert consensus statement. <i>Hpb</i> , 2015, 17, 691-699.	0.3	298
516	Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine. <i>Molecular Medicine Reports</i> , 2015, 12, 2247-2252.	2.4	8
517	18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 516-522.	1.3	11

#	ARTICLE	IF	CITATIONS
518	Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer, 2015, 15, 790.	2.6	39
519	Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature. Diagnostic Pathology, 2015, 10, 204.	2.0	16
520	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. Journal of Experimental and Clinical Cancer Research, 2015, 34, 156.	8.6	54
521	Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. Hepatology, 2015, 62, 1456-1465.	7.3	56
522	Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma. Liver International, 2015, 35, 2448-2457.	3.9	7
523	Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer, 2015, 121, 3290-3297.	4.1	95
524	Clinical Impact of Percutaneous Transhepatic Insertion of Metal Biliary Endoprostheses for Palliation of Jaundice and Facilitation of Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 489-494.	1.3	10
525	Malignant Transformation in Von-Meyenburg Complexes. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 607-614.	1.2	10
526	Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. Journal of Cancer, 2015, 6, 1099-1104.	2.5	89
527	Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. OncoTargets and Therapy, 2015, 8, 1899.	2.0	4
528	Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy—Long-Term Outcome of a Phase II Pilot Study. International Journal of Molecular Sciences, 2015, 16, 26619-26628.	4.1	29
529	MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. Journal of Clinical Medicine, 2015, 4, 1688-1712.	2.4	18
530	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. The Cochrane Library, 2015, , .	2.8	1
531	MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth <i>in vitro</i> and <i>in vivo</i> by targeting PTPN14 and PTEN. Oncotarget, 2015, 6, 5932-5946.	1.8	103
532	Percutaneous Intraluminal Radiofrequency Ablation for Malignant Extrahepatic Biliary Obstruction: A Safe and Feasible Method. Digestive Diseases and Sciences, 2015, 60, 2158-2163.	2.3	33
533	Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma. Tumor Biology, 2015, 36, 8367-8377.	1.8	21
534	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist, 2015, 20, 926-933.	3.7	15
535	Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. Oncology, 2015, 89, 345-350.	1.9	14

#	ARTICLE	IF	CITATIONS
536	Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor $\gamma$ (PPAR $\gamma$ ) in human cholangiocarcinoma. Digestive and Liver Disease, 2015, 47, 62-67.	0.9	6
537	Suggestions for Improving Perihilar Cholangiocarcinoma Staging Based on an Evaluation of the Seventh Edition AJCC System. Journal of Gastrointestinal Surgery, 2015, 19, 666-674.	1.7	12
538	Percutaneous Transhepatic Biliary Metal Stent for Malignant Hilar Obstruction: Results and Predictive Factors for Efficacy in 159 Patients from a Single Center. CardioVascular and Interventional Radiology, 2015, 38, 709-721.	2.0	34
539	Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 191-196.	2.3	8
540	Cost-effectiveness of preoperative biliary drainage for obstructive jaundice in pancreatic and periampullary cancer. Journal of Surgical Research, 2015, 193, 202-209.	1.6	11
541	Contrast-Enhanced Ultrasound of Focal Liver Lesions. American Journal of Roentgenology, 2015, 205, W56-W66.	2.2	175
542	Proteomics profiling of cholangiocarcinoma exosomes: A potential role of oncogenic protein transferring in cancer progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1989-1999.	3.8	54
543	The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complementary and Alternative Medicine, 2015, 15, 194.	3.7	57
544	The promise of metabolic phenotyping in gastroenterology and hepatology. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 458-471.	17.8	61
545	ACG Clinical Guideline: Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 646-659.	0.4	400
546	Transplantation for Primary Biliary Cirrhosis. , 2015, , 159-166.		0
547	Outcomes of Adjuvant Chemoradiation and Predictors of Survival After Extended Cholecystectomy in Gall Bladder Carcinoma: a Single Institution Experience from an Endemic Region. Journal of Gastrointestinal Cancer, 2015, 46, 48-53.	1.3	9
548	Clinical practice guidelines for the management of biliary tract cancers 2015: the 2 <sup>nd</sup> English edition. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 249-273.	2.6	205
549	Liver MRI. , 2015, , .		1
550	Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 711-718.	2.3	11
551	Analysis of the Roles of Glucose Transporter 1 and Hexokinase 2 in the Metabolism of Glucose by Extrahepatic Bile Duct Cancer Cells. Clinical Nuclear Medicine, 2015, 40, e178-e182.	1.3	13
552	Intrahepatic cholangiocarcinoma in a worker at an offset color proofâ€œprinting company: An autopsy case report. Hepatology Research, 2015, 45, 488-493.	3.4	8
554	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepatic Oncology, 2015, 2, 39-50.	4.2	10

#	ARTICLE	IF	CITATIONS
555	Structure and Bioactivities of Fungal Polysaccharides. , 2015, , 1851-1866.		2
556	Endoscopic stent placement combined with tumor ablation therapy. Gastrointestinal Intervention, 2015, 4, 27-30.	0.1	1
557	Targeted Therapy in Biliary Tract Cancers. Current Treatment Options in Oncology, 2015, 16, 48.	3.0	30
558	Intrahepatic Cholangiocarcinoma. Techniques in Vascular and Interventional Radiology, 2015, 18, 227-235.	1.0	8
559	Biliary Tree Abnormalities. , 2015, , 301-339.		0
560	MRI of cholangiocarcinoma. Journal of Magnetic Resonance Imaging, 2015, 42, 1165-1179.	3.4	76
561	Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. International Journal of Molecular Sciences, 2016, 17, 791.	4.1	39
562	RESULTADOS DEL TRATAMIENTO QUIRÚRGICO DEL COLANGIOCARCINOMA INTRAHEPÁTICO. Revista Chilena De Cirugía, 2016, 68, 154-163.	0.1	0
563	Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-8.	1.9	69
564	Novel Silicone-Coated 125I Seeds for the Treatment of Extrahepatic Cholangiocarcinoma. PLoS ONE, 2016, 11, e0147701.	2.5	5
565	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. International Journal of Molecular Sciences, 2016, 17, 2053.	4.1	14
566	A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin. American Journal of Therapeutics, 2016, 23, e1449-e1455.	0.9	4
567	FLT PET/CT Is Better Than FDG PET/CT in Differentiating Benign From Malignant Pancreatobiliary Lesions. Clinical Nuclear Medicine, 2016, 41, e244-e250.	1.3	5
568	Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy naïve pT2 gallbladder adenocarcinoma patients. Histopathology, 2016, 68, 722-728.	2.9	15
570	Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study. European Radiology, 2016, 26, 3500-3509.	4.5	3
571	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Translational Oncology, 2016, 9, 173-178.	3.7	22
572	Gallbladder Cancer. , 2016, , 115-125.		1
573	Surgical Oncology Manual. , 2016, , .		1



#	ARTICLE	IF	CITATIONS
574	Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm. <i>Annals of Surgical Oncology</i> , 2016, 23, 3009-3015.	1.5	50
575	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016, 114, 965-971.	6.4	39
576	Septin 2 accelerates the progression of biliary tract cancer and is negatively regulated by mir-140-5p. <i>Gene</i> , 2016, 589, 20-26.	2.2	32
577	Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells. <i>Oncology Reports</i> , 2016, 36, 1799-1806.	2.6	26
578	Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. <i>Cancer Science</i> , 2016, 107, 116-122.	3.9	32
579	Cancer related gene alterations can be detected with next-generation sequencing analysis of bile in diffusely infiltrating type cholangiocarcinoma. <i>Experimental and Molecular Pathology</i> , 2016, 101, 150-156.	2.1	11
580	Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1520-1525.	1.5	3
581	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	4.1	289
582	Cholangiocarcinoma and Gallbladder Cancer. , 2016, , 423-471.		0
583	Scientific Exhibits. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 148-190.	1.8	1
584	Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S32821.	1.3	40
585	Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. <i>BMC Gastroenterology</i> , 2016, 16, 117.	2.0	73
586	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. <i>Abdominal Radiology</i> , 2016, 41, 1937-1941.	2.1	24
587	Anti-CD155 and anti-CD112 monoclonal antibodies conjugated to a fluorescent mesoporous silica nanosensor encapsulating rhodamine 6G and fluorescein for sensitive detection of liver cancer cells. <i>Analyst</i> , The, 2016, 141, 4933-4940.	3.5	7
588	Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 91-98.	1.7	22
589	Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. <i>Acta Oncologica</i> , 2016, 55, 1168-1174.	1.8	18
590	Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 1699-1707.	1.5	76
591	Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. <i>Materials Science and Engineering C</i> , 2016, 60, 411-415.	7.3	28



#	ARTICLE	IF	CITATIONS
592	Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets. <i>Cancer Gene Therapy</i> , 2016, 23, 48-53.	4.6	24
593	miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. <i>Tumor Biology</i> , 2016, 37, 10553-10562.	1.8	50
595	Elevated <i>AQP1</i> Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 421-427.	1.9	8
596	Ultrasound of the liver, biliary tract, and pancreas. , 2017, , 245-275.e4.		2
597	Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 566-574.	1.0	21
598	miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. <i>Cell Death and Disease</i> , 2017, 8, e2770-e2770.	6.3	55
599	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. <i>United European Gastroenterology Journal</i> , 2017, 5, 104-110.	3.8	28
600	Collision and composite tumors; radiologic and pathologic correlation. <i>Abdominal Radiology</i> , 2017, 42, 2909-2926.	2.1	36
601	Decision Making: Intra-arterial Therapies for Cholangiocarcinoma—TACE and TARE. <i>Seminars in Interventional Radiology</i> , 2017, 34, 092-100.	0.8	30
602	Increased Expression of miR-29a and Its Prognostic Significance in Patients with Cholangiocarcinoma. <i>Oncology Research and Treatment</i> , 2017, 40, 128-132.	1.2	32
603	Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 11-31.	4.4	96
604	Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 156-162.	1.5	24
605	IRCAD recommendation on safe laparoscopic cholecystectomy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 603-615.	2.6	82
606	Gallbladder polypoid lesions >15 mm as indicators of T1b gallbladder cancer risk. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 156-158.	0.9	18
607	Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017, 411, 162-170.	7.2	10
608	Nodal areas of potential geographic error in adjuvant radiotherapy for biliary tract cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 365-373.	0.6	9
609	Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging. <i>Current Gastroenterology Reports</i> , 2017, 19, 58.	2.5	3
610	Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer. <i>Chemotherapy</i> , 2017, 62, 361-366.	1.6	8

#	ARTICLE	IF	CITATIONS
611	A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study. <i>Endoscopy</i> , 2017, 49, 977-982.	1.8	41
612	Actualización en cáncer de páncreas y de vías biliares. <i>Medicine</i> , 2017, 12, 1919-1928.	0.0	0
613	Prognostic significance of preoperative albumin-to-globulin ratio in patients with cholangiocarcinoma. <i>Current Research in Translational Medicine</i> , 2017, 65, 83-87.	1.8	11
614	Immunotherapeutic Approaches to Biliary Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 44.	3.0	8
615	Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 464-468.	1.7	10
616	Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 13-20.	1.1	25
617	Tea consumption and the risk of biliary tract cancer: a systematic review and dose-response meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 39649-39657.	1.8	17
618	Diet and biliary tract cancer risk in Shanghai, China. <i>PLoS ONE</i> , 2017, 12, e0173935.	2.5	27
619	Gemcitabine and capecitabine for advanced biliary cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 728-736.	1.4	6
620	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 314-323.	1.4	5
621	Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. <i>Cancer Letters</i> , 2018, 421, 161-169.	7.2	26
622	Clues to predict incidental gallbladder cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 149-154.	1.3	25
623	Emerging molecular target antagonists for the treatment of biliary tract cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 63-75.	2.4	14
624	Malignant Transformation Arising Within Unusual and Rare Hepatic Lesions: Fibropolycystic Disease Form of Ductal Plate Malformation and Biliary Adenofibroma. <i>International Journal of Surgical Pathology</i> , 2018, 26, 542-550.	0.8	9
625	Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 252-259.	1.1	1
626	Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5538-5550.	2.6	26
627	Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2018, 23, 443-451.	2.2	10
628	Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial. <i>Journal of Hepatology</i> , 2018, 68, 970-977.	3.7	79

#	ARTICLE	IF	CITATIONS
629	Artificial Neural Networking Model for the Prediction of Early Occlusion of Bilateral Plastic Stent Placement for Inoperable Hilar Cholangiocarcinoma. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2018, 28, e54-e58.	0.8	9
630	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. The Cochrane Library, 2018, 2018, CD011746.	2.8	51
631	Cholangiocarcinoma-associated genes identified by integrative analysis of gene expression data. Molecular Medicine Reports, 2018, 17, 5744-5753.	2.4	6
632	Surgical Resection and Prognostic Analysis of 142 Cases of Hilar Cholangiocarcinoma. Indian Journal of Surgery, 2018, 80, 309-317.	0.3	5
633	Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. Oncology, 2018, 94, 7-11.	1.9	13
634	Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment. Oncology, 2018, 94, 72-78.	1.9	11
635	PET/CT in Gall Bladder and Biliary Tract Malignancies. , 2018, , 75-84.		1
636	Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1335-1344.	3.8	55
637	Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Current Problems in Cancer, 2018, 42, 49-58.	2.0	25
638	Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Annals of Hepatology, 2018, 17, 274-285.	1.5	29
639	Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Annals of Hepatology, 2018, 17, 604-614.	1.5	50
640	14 Tumoren der Gallenwege. , 2018, , .		0
641	42 Malignant Biliary Disease. , 2018, , .		0
642	A retrospective review of correlative radiological assessment and surgical exploration for hilar cholangiocarcinoma. Annals of Hepato-biliary-pancreatic Surgery, 2018, 22, 216.	0.1	5
643	Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. Biochemical and Biophysical Research Communications, 2018, 504, 654-659.	2.1	23
644	Drenagem biliar pr� operat�ria no c�ncer de cabe�sa de p�ncreas. , 2018, 97, 422-432.	0.1	0
645	Synergistic anti-proliferative effect of mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	9
646	Safety and Efficacy of Low-Dose Single-Agent Capecitabine in Inoperable Gallbladder Cancer with Jaundice Post-Single-System Single-Catheter External Biliary Drainage: a Pilot Study from a Highly Endemic Area. Indian Journal of Surgical Oncology, 2018, 9, 530-537.	0.7	2

#	ARTICLE	IF	CITATIONS
647	Guided chemotherapy based on patientâ€derived miniâ€xenograft models improves survival of gallbladder carcinoma patients. <i>Cancer Communications</i> , 2018, 38, 1-9.	9.2	32
648	The population-based incidence and mortality of biliary tract cancer in Sweden. <i>Cancer Epidemiology</i> , 2018, 56, 14-20.	1.9	6
649	Patient-Provider Communication and Health Outcomes Among Individuals with Hepato-Pancreato-Biliary Disease in the USA. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 624-632.	1.7	10
650	Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. <i>Biomedical Reports</i> , 2018, 9, 42-52.	2.0	6
651	Smoking, Alcohol Consumption, and Risks for Biliary Tract Cancer and Intrahepatic Bile Duct Cancer. <i>Journal of Epidemiology</i> , 2019, 29, 180-186.	2.4	18
652	Biliary Tract Tumors. , 2019, , 1323-1339.		2
653	Digital single-operator cholangioscopy: a useful tool for selective guidewire placements across complex biliary strictures. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 731-737.	2.4	44
654	Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 815-820.	1.4	14
655	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42 2019, 9, e028147.	1.9	14
656	Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options. <i>Oncology</i> , 2019, 97, 191-201.	1.9	8
657	Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1527-1535.	4.2	30
658	Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden. <i>Acta OncolÃ³gica</i> , 2019, 58, 290-295.	1.8	11
659	UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals. <i>Biochemical Pharmacology</i> , 2019, 166, 174-184.	4.4	16
660	&lt;p&gt;Biliary tract cancers: current knowledge, clinical candidates and future challenges&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2623-2642.	1.9	78
661	&lt;p&gt;lncRNAs as potential molecular biomarkers in the clinicopathology and prognosis of cholangiocarcinoma: a systematic review and meta-analysis&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1905-1915.	2.0	11
662	Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma. <i>Cell Death and Disease</i> , 2019, 10, 231.	6.3	9
663	Effect of proximity to specialty care on outcomes for biliary cancers: a population-based retrospective cohort study. <i>CMAJ Open</i> , 2019, 7, E131-E139.	2.4	7
664	Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer. <i>Pathology International</i> , 2019, 69, 86-93.	1.3	3

#	ARTICLE	IF	CITATIONS
665	Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. <i>Annals of Oncology</i> , 2019, 30, 788-795.	1.2	73
666	<p>The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10871-10882.	1.9	4
667	A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00022.	2.5	24
668	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019, 10, 6185-6190.	2.5	7
669	A novel prognostic model for diagnosing atypical bile duct hyperplasia in patients with intrahepatic lithiasis. <i>Medicine (United States)</i> , 2019, 98, e15364.	1.0	1
670	Staging laparoscopy among three subtypes of extrahepatic biliary malignancy: a 15-year experience from 10 institutions. <i>Journal of Surgical Oncology</i> , 2019, 119, 288-294.	1.7	12
671	Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. <i>Gut</i> , 2019, 68, 1458-1464.	12.1	23
672	Increased prevalence of pancreaticobiliary maljunction in biliary malignancies. <i>Scandinavian Journal of Surgery</i> , 2019, 108, 285-290.	2.6	14
673	Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1108-1115.	2.8	6
674	PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 162-173.	1.5	16
675	Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location. <i>Medical Molecular Morphology</i> , 2020, 53, 42-49.	1.0	8
676	Liver and Bile Duct Cancer. , 2020, , 1314-1341.e11.		8
677	Advanced ERCP for Complicated and Refractory Biliary and Pancreatic Diseases. , 2020, , .		0
678	Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 684-693.	1.0	38
679	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020, 40, 704-711.	3.9	42
680	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	1.5	4
681	Pulmonary metastasis of distal cholangiocarcinoma with multiple cavities in bilateral lungs: A case report. <i>Thoracic Cancer</i> , 2020, 11, 2998-3000.	1.9	1
682	Histological evaluation of tumor differentiation score and prognosis of extrahepatic bile duct cancer: A proposal for a new histological grading system. <i>Pathology International</i> , 2020, 70, 857-864.	1.3	5

#	ARTICLE	IF	CITATIONS
683	Appraisal of the current guidelines for management of cholangiocarcinoma using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Hepatobiliary Surgery and Nutrition, 2020, 9, 126-135.	1.5	18
684	In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines. Drug Design, Development and Therapy, 2020, Volume 14, 2319-2334.	4.3	11
685	Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer: An Italian Pooled Analysis. Anticancer Research, 2020, 40, 3417-3421.	1.1	8
686	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. Hepatobiliary Surgery and Nutrition, 2020, 9, 13-24.	1.5	11
687	JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16492-16499.	7.1	43
688	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	4.5	64
689	Biliary tract cancers: systemic therapy for advanced disease. Chinese Clinical Oncology, 2020, 9, 5-5.	1.2	7
690	Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chinese Clinical Oncology, 2020, 9, 2-2.	1.2	38
691	Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era. Oncologist, 2020, 25, 447-453.	3.7	4
692	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. Oncologist, 2020, 25, 886-893.	3.7	27
693	A Systematic Review and Network Meta-Analysis of Adjuvant Therapy for Curatively Resected Biliary Tract Cancers. Current Oncology, 2020, 27, 20-26.	2.2	8
694	Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers. Journal of Gastrointestinal Cancer, 2021, 52, 294-299.	1.3	2
695	Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	4.5	15
696	The prognostic impact of peritoneal washing cytology for otherwise resectable extrahepatic cholangiocarcinoma patients. Surgery Today, 2021, 51, 1227-1231.	1.5	1
697	Surgical Approach to the Treatment of Cholangiocarcinoma. , 2021, , 319-338.		0
698	Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy, 2021, Volume 14, 1341-1366.	2.0	12
699	Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. Epidemiology and Health, 2021, 43, e2021011.	1.9	17
700	The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study. Journal of Oncology, 2021, 2021, 1-7.	1.3	2

#	ARTICLE	IF	CITATIONS
701	Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Research and Treatment, 2021, 53, 471-479.	3.0	2
702	How Can We Manage Gallbladder Lesions by Transabdominal Ultrasound?. Diagnostics, 2021, 11, 784.	2.6	9
703	Proton Pump Inhibitors Increase the Risk of Early Biliary Infection After Placement of Percutaneous Transhepatic Biliary Stents. Journal of Vascular and Interventional Radiology, 2021, 32, 569-575.	0.5	5
704	Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 101-107.	1.6	4
705	Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers, 2021, 13, 3657.	3.7	55
706	Porphylioprotein Accumulation and Porphylioprotein Photodynamic Therapy Effects Involving Cancer Cell-Specific Cytotoxicity. International Journal of Molecular Sciences, 2021, 22, 7306.	4.1	5
707	Synergistic combination of cytotoxic chemotherapy and cyclinâ€¢dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology, 2022, 75, 43-58.	7.3	6
708	Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer. BMC Cancer, 2021, 21, 953.	2.6	0
709	Is surgery justified for elderly patients with extrahepatic cholangiocarcinoma? Reappraisal from a viewpoint of comorbidity and organ function. Surgery Today, 2021, 51, 1787-1794.	1.5	4
710	Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer. Cancers, 2021, 13, 4581.	3.7	19
711	Endoscopic Management of Cholangiocarcinoma. , 2021, , 291-305.		0
712	Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2435-2445.	2.5	11
713	Diagnostic Accuracy and Therapeutic Efficacy of Digital Single-Operator Cholangioscopy for Biliary Lesions and Stenosis. Digestion, 2021, 102, 776-782.	2.3	5
714	Biliary Neoplasms. , 2021, , 1437-1448.		0
716	Proteomics of Human Bile. , 2007, , 399-414.		7
717	Structure and Bioactivities of Fungal Polysaccharides. , 2014, , 1-14.		3
719	Epidemiology of Cholangiocarcinoma and Gallbladder Carcinoma. Medical Radiology, 2014, , 1-31.	0.1	3
720	Chirurgische Therapie von Karzinomen der extrahepatischen Gallenwege und der Gallenblase. , 2001, , 577-617.		1



#	ARTICLE	IF	CITATIONS
721	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1063-1078.	2.3	14
723	Disorders of the Liver and Biliary Tract. , 2010, , 1153-1171.		4
724	The Hepatobiliary System. , 2009, , 263-289.		2
725	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
726	Neoplasms of the Gallbladder and Biliary Tract. , 2008, , 1467-1487.		5
728	Gallbladder and Biliary Tract Disease. , 2010, , 502-505.e1.		4
729	Liver Cancer. , 2006, , 763-786.		63
730	Biliary Tract Cancer. , 2006, , 787-800.		47
731	Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 682-686.	1.4	3
732	Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer. <i>BMC Gastroenterology</i> , 2020, 20, 20.	2.0	5
733	Atypical presentation of an advanced obstructive biliary cancer without jaundice. <i>American Journal of Case Reports</i> , 2013, 14, 462-466.	0.8	2
734	Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients. <i>Medical Science Monitor</i> , 2015, 21, 2375-2381.	1.1	19
735	Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. <i>F1000Research</i> , 2017, 6, 1643.	1.6	6
736	Diagnostic-therapeutic management of bile duct cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 1732-1752.	0.8	18
737	Feasibility of Contrast-Enhanced Photoacoustic Liver Imaging at a Wavelength of 1064 nm. , 2012, , .		4
738	Real-Time PCR-Based Analysis of the Human Bile MicroRNAome Identifies miR-9 as a Potential Diagnostic Biomarker for Biliary Tract Cancer. <i>PLoS ONE</i> , 2011, 6, e23584.	2.5	129
739	Preoperative C-reactive protein as a prognostic factor for recurrence after surgical resection of biliary tract cancer. <i>Korean Journal of Clinical Oncology</i> , 2015, 11, 101-105.	0.1	3
740	Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma. <i>Oncotarget</i> , 2016, 7, 70378-70387.	1.8	18



#	ARTICLE	IF	CITATIONS
741	Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. <i>Oncotarget</i> , 2016, 7, 85492-85501.	1.8	22
742	Overexpression of karyopherin- $\beta 2$ in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. <i>Oncotarget</i> , 2017, 8, 42159-42172.	1.8	17
743	Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma <i>via</i> activating Akt/NF- $\kappa$ B signaling by paracrine CCL5. <i>Oncotarget</i> , 2017, 8, 73693-73704.	1.8	45
744	Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. <i>Oncotarget</i> , 2017, 8, 79441-79452.	1.8	26
745	Reduced levels of N <sup>6</sup> -methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival. <i>Oncotarget</i> , 2017, 8, 112598-112609.	1.8	12
746	Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 3178-3194.	1.8	43
747	Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 18631-18640.	1.8	52
748	Involvement of Wnt/ $\beta$ -catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 42276-42289.	1.8	86
749	The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. <i>Oncotarget</i> , 2016, 7, 745-758.	1.8	38
750	Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1. <i>Oncotarget</i> , 2016, 7, 10271-10282.	1.8	29
751	Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. <i>Current Drug Delivery</i> , 2020, 17, 826-844.	1.6	13
752	Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells. <i>Anticancer Research</i> , 2016, 36, 6109-6116.	1.1	11
753	Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer. <i>Anticancer Research</i> , 2017, 37, 7049-7056.	1.1	4
754	Clinical Profile and Outcome of Gall Bladder Carcinoma. <i>International Journal of Advanced Multidisciplinary Research</i> , 2017, 4, 14-26.	0.2	2
755	Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: Detection by oligonucleotide microarray and real-time PCR analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 2501.	3.3	33
756	Cholangiocarcinoma: A 7-year experience at a single center in Greece. <i>World Journal of Gastroenterology</i> , 2008, 14, 6213.	3.3	10
757	Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. <i>World Journal of Gastroenterology</i> , 2008, 14, 7021.	3.3	11
758	Diagnostic and surgical therapeutic features of extrahepatic bile duct carcinoma without jaundice. <i>World Journal of Gastroenterology</i> , 2004, 10, 3060.	3.3	7

#	ARTICLE	IF	CITATIONS
759	Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: Two decades of experience at Chang Gung Memorial Hospital. World Journal of Gastroenterology, 2005, 11, 1779.	3.3	54
760	Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World Journal of Gastroenterology, 2005, 11, 3392.	3.3	155
761	MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2005, 11, 4939.	3.3	49
762	Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas. World Journal of Gastroenterology, 2006, 12, 1889.	3.3	3
763	Immunohistochemical expression of mismatch repair genes: A screening tool for predicting mutator phenotype in liver fluke infection-associated intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2006, 12, 3740.	3.3	17
764	Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World Journal of Gastroenterology, 2006, 12, 6500.	3.3	53
765	Early bile duct cancer. World Journal of Gastroenterology, 2007, 13, 3409.	3.3	13
766	Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World Journal of Gastroenterology, 2007, 13, 4761.	3.3	19
767	Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma. World Journal of Gastroenterology, 2007, 13, 1422.	3.3	33
768	Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography. World Journal of Gastroenterology, 2010, 16, 237.	3.3	16
769	Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World Journal of Gastroenterology, 2010, 16, 3567.	3.3	19
770	Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. World Journal of Gastroenterology, 2011, 17, 2924.	3.3	8
771	Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World Journal of Gastroenterology, 2011, 17, 4023.	3.3	38
772	Adjuvant treatment in biliary tract cancer: To treat or not to treat?. World Journal of Gastroenterology, 2012, 18, 2591.	3.3	24
773	Survival analysis of cholangiocarcinoma: A 10-year experience in Malaysia. World Journal of Gastroenterology, 2012, 18, 458.	3.3	21
774	Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer. World Journal of Gastroenterology, 2013, 19, 9334.	3.3	5
775	Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2014, 20, 4076.	3.3	33
776	Optimum chemotherapy for the management of advanced biliary tract cancer. World Journal of Gastroenterology, 2015, 21, 4121.	3.3	10

#	ARTICLE	IF	CITATIONS
777	MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor. <i>Molecular Medicine Reports</i> , 2015, 12, 1549-1555.	2.4	32
778	Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. <i>Translational Gastrointestinal Cancer</i> , 2012, 1, 58-70.	3.0	97
779	Progranulin: a novel regulator of gastrointestinal cancer progression. <i>Translational Gastrointestinal Cancer</i> , 2013, 2, 145-151.	3.0	20
780	Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1127-1139.	3.0	25
781	New insights on cholangiocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 136.	2.0	54
782	Imaging pancreatobiliary ductal system with optical coherence tomography: A review. <i>World Journal of Gastrointestinal Endoscopy</i> , 2013, 5, 540.	1.2	10
783	Extrahepatic biliary cancer: New staging classification. <i>World Journal of Radiology</i> , 2012, 4, 345.	1.1	21
784	Management Strategies for Gallbladder Polyps: Is It Possible to Predict Malignant Gallbladder Polyps?. <i>Gut and Liver</i> , 2008, 2, 88-94.	2.9	83
785	Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. <i>Gut and Liver</i> , 2009, 3, 298-305.	2.9	153
786	A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1. <i>Gut and Liver</i> , 2013, 7, 371-376.	2.9	7
787	A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer. <i>Gut and Liver</i> , 2013, 7, 594-598.	2.9	9
788	IgG4-Associated Cholangitis Can Mimic Hilar Cholangiocarcinoma. <i>Gut and Liver</i> , 2015, 9, 556.	2.9	13
789	Surgical strategy for bile duct cancer: Advances and current limitations. <i>World Journal of Clinical Oncology</i> , 2011, 2, 94.	2.3	54
790	Current Status of Photodynamic Therapy for Bile Duct Cancer. <i>Clinical Endoscopy</i> , 2013, 46, 38.	1.5	37
791	Linking <i>Helicobacter pylori</i> with gallbladder and biliary tract cancer in Moroccan population using clinical and pathological profiles. <i>Bioinformation</i> , 2019, 15, 735-743.	0.5	8
792	Gallbladder Cancer: a Subtype of Biliary Tract Cancer Which is a Current Challenge in China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1317-1320.	1.2	10
793	Treatment Outcome of Palliative Chemotherapy in Inoperable Cholangiocarcinoma in Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3565-3568.	1.2	22
794	Association of CYP39A1, RUNX2 and Oxidized Alpha-1 Antitrypsin Expression in Relation to Cholangiocarcinoma Progression. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10187-10192.	1.2	10

#	ARTICLE	IF	CITATIONS
795	Cholangiocarcinoma and AIDS-Related Sclerosing Cholangitis. <i>Annals of Internal Medicine</i> , 2000, 132, 1006.	3.9	14
796	Colon Mass as a Secondary Metastasis from Cholangiocarcinoma: A Diagnostic and Therapeutic Dilemma. <i>Cureus</i> , 2016, 8, e707.	0.5	2
797	Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5145-5160.	2.0	14
798	RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. <i>Journal of Clinical Medicine</i> , 2021, 10, 4652.	2.4	1
799	Extrahepatic Cholestasis. , 2000, , 159-186.		0
800	Biliary tract. <i>Current Opinion in Gastroenterology</i> , 2000, 16, 431.	2.3	0
801	Maligne Tumoren der Leber und Gallenwege. , 2001, , 357-376.		2
802	Cancers of the large bowel and hepatobiliary tract. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 509-534.	0.5	0
803	Erkrankungen von Leber, Gallenwegen und Pankreas. , 2003, , 863-954.		0
804	Gastrointestinal Cancers. <i>Medical Radiology</i> , 2003, , 49-80.	0.1	0
805	Gallenwegstents. , 2003, , 275-282.		0
806	Gallbladder and Biliary Diseases: More Common in Women, More Severe in Men. , 2004, , 446-453.		0
807	Cancers of the large bowel and hepatobiliary tract. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 443-469.	0.5	0
808	Liver Transplantation for Primary Biliary Cirrhosis. , 2005, , 177-186.		0
809	Cholangiozelluläres Karzinom. , 2006, , 4027-4044.		0
810	Leber- und Gallenwegs-tumoren. , 2006, , 183-203.		0
811	Pharmacogenetics in Gastroenterology. , 2006, , 273-294.		0
812	Genetics and Molecular Biology of Pancreatic and Biliary Cancers. , 2007, , 136-152.		0

#	ARTICLE	IF	CITATIONS
813	Approach to Solid Liver Masses in the Cirrhotic Patient. Gastroenterology Research, 2009, 2, 259-267.	1.3	1
814	Cholangiocellular carcinoma: medical and interventional endoscopic strategies, new options. , 2009, , 61-78.		0
815	Hilar Cholangiocarcinoma: Photodynamic Therapy and Stenting. , 2009, , 463-483.		0
816	Evaluation of Focal Liver Masses. , 2010, , 173-179.		0
817	Perihilar Bile Ducts. , 2010, , 219-225.		1
818	Malignant Tumors. , 2010, , 1519-1566.		0
819	Chirurgische Therapie von Karzinomen der Gallenblase und der extrahepatischen Gallenwege. , 2010, , 655-680.		0
820	Perihilar Bile Ducts. , 2010, , 263-269.		0
821	Comportamiento del c�ncer de ves�cula biliar en pacientes colecistectomizados del Hospital Universitario de Neiva (HUN) durante el periodo 1 de enero de 2005 al 31 de diciembre de 2008. RFS Revista Facultad De Salud, 2010, 2, 43-48.	0.0	0
822	Carcinoma of the Biliary Tract. , 2011, , 251-299.		1
823	Neoplasms of Extrahepatic Bile Ducts. Molecular Pathology Library, 2011, , 881-890.	0.1	0
829	A Case of Recurrent Gallbladder Cancer with Complete Response to Gemcitabine plus S-1 Combination Chemotherapy. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 120-123.	0.0	0
830	Liver transplantation for cholangiocarcinoma and other neoplastic diseases. , 2012, , 1712-1721.e1.		1
831	A Case of Adenocarcinoma in situ of the Distal Common Bile Duct Diagnosed by Percutaneous Transhepatic Cholangioscopy. Korean Journal of Internal Medicine, 2012, 27, 211.	1.7	3
832	Pathology of the gallbladder and extrahepatic bile ducts. , 2012, , 490-513.		0
833	The Role of the Tumor Microenvironment in the Pathogenesis of Cholangiocarcinoma. , 0, , .		1
835	Gemcitabine Alone or in Combination with Cisplatin for Advanced Biliary Tract Carcinomas: an Overview of Clinical Evidence. Asian Pacific Journal of Cancer Prevention, 2013, 14, 877-883.	1.2	5
837	Liver and Bile Duct Cancer. , 2014, , 1373-1396.e8.		5

#	ARTICLE	IF	CITATIONS
839	Gall stones size, number, biochemical analysis and lipidogram- an association with gall bladder cancer: a study of 200 cases. International Journal of Cancer Therapy and Oncology, 2014, 2, 020310.	0.2	2
840	Tumoren der Gallenwege. , 2015, , 1-8.		0
841	A Case of In-Stent Restenosis-Predictors of Risk and Treatment Modalities. Journal of Cardiology & Current Research, 2015, 3, .	0.1	0
843	Pathologic Features of Primary and Metastatic Hepatic Malignancies. Cancer Treatment and Research, 2016, 168, 257-293.	0.5	0
844	Liver transplantation for nonhepatocellular malignant disease. , 2017, , 1791-1800.e2.		0
845	Tumoren der Gallenwege. , 2018, , 473-479.		0
846	Coâ€‘presentation of obstructive jaundice and primary hyperparathyroidism leading to diagnosis of cholangiocarcinoma. Open Access Journal of Translational Medicine & Research, 2018, 2, .	0.1	0
847	Selective internal radiation therapy (SIRT) with yttrium-90 microspheres for unresectable intrahepatic cholangiocarcinoma. BMJ Case Reports, 2018, 2018, bcr-2017-223539.	0.5	0
848	Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. Journal of Gastrointestinal Oncology, 2018, 9, 762-768.	1.4	5
849	Hybrid Imaging for Malignant Conditions of the Gastrointestinal Tract. , 2019, , 841-857.		0
851	STUDY OF INCIDENTAL CARCINOMA ON ROUTINE CHOLECYSTECTOMY SPECIMENS - A STORY OF A DILIGENT PATHOLOGIST. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 1514-1518.	0.0	0
853	SEMS Insertion for Malignant Hilar Stricture: ERCP Versus the Percutaneous Approach. , 2020, , 87-107.		0
854	Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling. World Journal of Gastroenterology, 2020, 26, 4356-4371.	3.3	6
855	A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. Journal of Gastrointestinal Oncology, 2020, 11, 1421-1430.	1.4	2
856	miRâ€™125b suppresses cellular proliferation by targeting câ€™FLIP in gallbladder carcinoma. Oncology Letters, 2019, 18, 6822-6828.	1.8	1
857	Gallbladder Cancer. , 2020, , 183-197.		0
858	Establishment and characterization of patient-derived primary cell lines as preclinical models for gallbladder carcinoma. Translational Cancer Research, 2020, 9, 1698-1710.	1.0	2
860	Special Lecture: Future perspectives in the treatment of biliary tumour disease: a multidisciplinary approach. , 0, , 67-73.		0

#	ARTICLE	IF	CITATIONS
862	Neoplasien des Pankreas und der Gallenwege. , 2007, , 976-984.		0
863	Primary Sclerosing Cholangitis V â€” With Intrahepatic Cholangiocarcinoma. , 2007, , 228-229.		0
864	Primary Sclerosing Cholangitis VI â€” With Hilar Cholangiocarcinoma. , 2007, , 230-231.		0
866	Medical Oncology. , 2008, , 528-780.		0
869	Primary squamous cell carcinoma of the main hepatic bile duct. Canadian Journal of Surgery, 2008, 51, E85-6.	1.2	8
870	Effective treatment strategies for cholangiocarcinoma: the challenge remains. Gastrointestinal Cancer Research: GCR, 2008, 2, 251-2.	0.7	4
871	Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointestinal Cancer Research: GCR, 2011, 4, 155-60.	0.7	26
872	Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Translational Gastrointestinal Cancer, 2012, 1, 71-80.	3.0	41
873	Molecular targeted therapy for biliary tract malignancy: defining the target. Hepatobiliary Surgery and Nutrition, 2012, 1, 53-4.	1.5	5
874	Case 1-2011: a 26 year-old man with right lower limb edema and liver mass. Middle East Journal of Digestive Diseases, 2011, 3, 62-71.	0.4	0
875	Comparative Study Between Two Treatment Regimens of Cisplatin-5-Fluorouracil and Gemcitabine-Cisplatin in Gallbladder Cancer Patients. Iranian Journal of Pharmaceutical Research, 2017, 16, 798-804.	0.5	2
876	Histological classification of microvascular invasion to predict prognosis in intrahepatic cholangiocarcinoma. International Journal of Clinical and Experimental Pathology, 2017, 10, 7674-7681.	0.5	5
877	Widening Health Disparities: Increasing Cholangiocarcinoma Incidence in an Underserved Population. , 2022, 1, 180-185.		1
878	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms. Journal of Gastrointestinal Surgery, 2022, 26, 1213-1223.	1.7	0
880	Specific Bile Microorganisms Caused by Intra-Abdominal Abscess on Pancreaticoduodenectomy Patients: A Retrospective Cohort Study. Current Oncology, 2022, 29, 111-121.	2.2	5
881	Percutaneous biliary stent combined with brachytherapy using <sup>125</sup> I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World Journal of Clinical Cases, 2021, 9, 10979-10993.	0.8	1
882	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of Chemotherapy, 2022, 34, 543-549.	1.5	1
883	The pancreas and extrahepatic biliary system. , 2015, , 2146-2202.		1



#	ARTICLE	IF	CITATIONS
887	Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS ONE, 2022, 17, e0266707.	2.5	4
889	Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction. Clinical and Experimental Hepatology, 2022, 8, 70-77.	1.3	7
890	Systematic review of squamous cell carcinoma of the gallbladder. American Journal of Surgery, 2022, 224, 863-868.	1.8	2
891	Liver Transplant for Non-Hepatocellular Malignancies: A Review for Radiologists. American Journal of Roentgenology, 2022, , .	2.2	1
892	Neoplasms of the Gallbladder and Biliary Tract. , 2015, , 1402-1426.		0
895	Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. Journal of Gastrointestinal Surgery, 2003, 7, 850-856.	1.7	1
896	<i>Helicobacter bilis</i> infection induces oxidative stress in and enhances the proliferation of human cholangiocytes. Helicobacter, 0, , .	3.5	2
897	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precision Oncology, 2022, , .	3.0	11
898	Etiology, Clinical Presentations, and Short-Term Treatment Outcomes of Extrahepatic Obstructive Jaundice in South-Western Uganda. Clinical and Experimental Gastroenterology, 0, Volume 15, 79-90.	2.3	1
899	Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	2
900	Association Between Socioeconomic and Insurance Status and Delayed Diagnosis of Gastrointestinal Cancers. Journal of Surgical Research, 2022, 279, 170-186.	1.6	6
901	Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211153.	3.2	4
902	Body Mass Index Trajectories, Weight Gain, and Risks of Liver and Biliary Tract Cancers. JNCI Cancer Spectrum, 2022, 6, .	2.9	2
903	Surgical Treatment of Distal Cholangiocarcinoma. Current Oncology, 2022, 29, 6674-6687.	2.2	6
904	PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis. Journal of Inflammation Research, 0, Volume 15, 6031-6046.	3.5	0
905	Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. Journal of Oncology Pharmacy Practice, 0, , 107815522211220.	0.9	0
906	Anatomical hepatectomy for achieving textbook outcome for perihilar cholangiocarcinoma treated with curative-intent resection: A multicenter study. , 2022, 1, 245-251.		2
907	Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma. Clinical and Translational Oncology, 0, , .	2.4	0

#	ARTICLE	IF	CITATIONS
909	Treating Biliary Tract Cancers: New Targets and Therapies. <i>Drugs</i> , 2022, 82, 1629-1647.	10.9	2
910	The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF- $\kappa$ B1 p105 to p50. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	2
911	Second line drug therapy for biliary cancer. <i>Meditinskiy Sovet</i> , 2022, , 136-147.	0.5	0
912	Comparison of Efficacy and Safety between Endoscopic Retrograde Cholangiopancreatography and Percutaneous Transhepatic Cholangial Drainage for the Treatment of Malignant Obstructive Jaundice: A Systematic Review and Meta-Analysis. <i>Digestion</i> , 2023, 104, 85-96.	2.3	2
913	Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases. <i>Pharmacological Research</i> , 2023, 189, 106706.	7.1	13
914	Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three-dimensional reconstruction volumetry. <i>Cancer Medicine</i> , 0, , .	2.8	1
915	Emerging treatment strategies in hepatobiliary cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 243-256.	2.4	1
916	Primary Squamous Cell Carcinoma of Gallbladder With Hepatic Invasion. <i>Cureus</i> , 2023, , .	0.5	0
917	Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site. <i>Hpb</i> , 2023, , .	0.3	0
919	Artificial intelligence in medical imaging for cholangiocarcinoma diagnosis: A systematic review with scientometric analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 874-882.	2.8	5
920	Main causes of death in advanced biliary tract cancer. <i>Cancer Medicine</i> , 0, , .	2.8	1
921	Safety and efficacy of self-expandable metallic stent combined with 125I brachytherapy for the treatment of malignant obstructive jaundice. <i>Cancer Imaging</i> , 2023, 23, .	2.8	2
923	Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the OncoPrint Focus DNA assay: clinical and diagnostic implications. <i>Molecular Biology Reports</i> , 2023, 50, 7113-7120.	2.3	1
924	An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study. <i>BMC Gastroenterology</i> , 2023, 23, .	2.0	0
925	Prognostic impact of lung recurrence in patients with biliary tract cancer. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	1.9	0
926	Lymph node dissection results, surgical management modalities and oncologic results of intrahepatic cholangiocarcinomas, single center experience. <i>Akademik Gastroenteroloji Dergisi</i> , 2023, 22, 85-89.	0.1	0
927	Diagnostic Role of Bile Pigment Components in Biliary Tract Cancer. <i>Biomolecules and Therapeutics</i> , 2023, , .	2.4	0
929	Very rare metastatic phenomena of biliary tract cancer to the cerebellum: A case report and review of the literature. <i>International Journal of Surgery Case Reports</i> , 2023, 111, 108819.	0.6	0

#	ARTICLE	IF	CITATIONS
930	Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer. Langenbeck's Archives of Surgery, 2023, 408, .	1.9	0
931	Prognostic impact of peritoneal washing cytology in patients with biliary tract cancer. Langenbeck's Archives of Surgery, 2024, 409, .	1.9	0
932	Downregulation of dermatopontin in cholangiocarcinoma cells suppresses CCL19 secretion of macrophages and immune infiltration. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
933	Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches. Cancers, 2024, 16, 801.	3.7	0